---
title: "Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Clinical evidence. Covers Voyage, Panorama, MMED008, LSD-assist, LDA1, and MM-120-101. 416 evidence topics quoted from 50 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 Voyage

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Objective: efficacy and safety of a single 100 µg dose of DT120 versus placebo

> “To report topline efficacy and safety results from Voyage (NCT06741228), a phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating a single 100-μg dose of DT120 in adults with GAD”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.1-2"></a>

###### Registered official title

> “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.1-3"></a>

###### Part B objective: maintenance of efficacy and retreatment patterns

> “Part A evaluated acute efficacy and safety over 12 weeks following a single administration of DT120”
> “Part B evaluated the maintenance of efficacy and safety and retreatment patterns over an additional 40 weeks”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Sites: approximately 35 in the United States

> “The study enrolled 214 participants aged 18 to 74 years across approximately 35 sites in the United States”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.2-2"></a>

###### Registered locations: 34 sites in the United States

> “This study has 34 locations”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.2-3"></a>

###### Registered study dates

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2024-12-11” |
| Primary completion (actual) | “2026-07-15” |
| Study completion (estimated) | “2027-04” |
| Recruitment status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.2-4"></a>

###### First participant dosed: December 2024

> “today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

> “Initiated dosing in the Phase 3 Voyage study of MM120 ODT for the treatment of GAD in the fourth quarter of 2024.”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

<a id="topic-3.1.1.2-5"></a>

###### Topline results (Part A) reported: August 12, 2026

> “On August 12, 2026, we announced that the Voyage study met its primary endpoint and all key secondary efficacy endpoints”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.1.2-6"></a>

###### Topline timing: early third quarter of 2026, February to May 2026, superseded in August 2026

> “Topline data are anticipated in early 3Q 2026.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “In December 2024, we announced the initiation of Voyage, and we anticipate a topline readout (Part A results) in early third quarter 2026.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “Topline data expected in early 3Q 2026.”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.1.2-7"></a>

###### Topline timing: second quarter of 2026, January 2026, superseded in February 2026

> “2Q 2026: Topline data from Voyage – the first Phase 3 study of DT120 ODT in GAD”

Source: [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)

<a id="topic-3.1.1.2-8"></a>

###### Topline timing: first half of 2026, March to November 2025, superseded in January 2026

> “Topline data from the 12-week double-blind period (Part A) is anticipated in the first half of 2026.”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates); [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

> “Topline data for Voyage is expected in the first half of 2026 and for Panorama and Emerge in the second half of 2026.”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Design: phase 3, multicenter, randomized, double-blind, placebo-controlled

> “Voyage is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a single 100 µg dose of DT120 ODT versus placebo in adults with generalized anxiety disorder (GAD). The study consists of a 12-week double-blind period (Part A) followed by a 40-week open-label extension (Part B), during which participants may be eligible to receive up to four additional doses of DT120 ODT based on symptom severity.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.3-2"></a>

###### Part A and Part B: 12-week parallel-group period and 40-week extension

> “Both trials are comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel-group trial assessing the efficacy and safety of DT120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with DT120 ODT, subject to certain conditions for treatment eligibility.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.1.3-3"></a>

###### Randomization: 1:1 to DT120 or placebo

> “The study consisted of a 12-week, randomized, double-blind, single-dose administration period in which participants were randomized 1:1 to DT120 or placebo (Part A), followed by a 40-week extension phase where participants had the opportunity for open-label treatment (Part B; Figure 1)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Two-arm framework without a low-dose comparator

> “Voyage and Emerge established a 2-arm framework of DT120 100 μg versus placebo to characterize target dose efficacy and safety. Panorama and Ascend added DT120 50 μg as a low-dose comparator, thereby creating a 3-arm framework to evaluate efficacy and safety as well as mitigate functional unblinding (Figure 1)”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.3-5"></a>

###### Masking: participants and treating clinicians, identical placebo tablet

> “This study is double-blinded, which means that both the participants and the treating clinicians will be masked to treatment allocation, meaning neither party will know which participants are receiving the active drug and which are receiving the placebo. The placebo tablet is identical looking to the active drug”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.3-6"></a>

###### Central raters blinded to treatment assignment and visit number

> “In Voyage, HAM-A ratings were assessed by central raters blinded to both treatment assignment and visit number.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “Participants, DSMs, central raters, and dosing sites were blinded to treatment and primary endpoint data”
> “HAM-A (GAD) or MADRS (MDD) central raters were independent from the dosing site and blinded to treatment and visit number”
> “Site raters could not serve as the DSM or HCP for the same participant after the screening or baseline assessments to mitigate functional unblinding”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.3-7"></a>

###### Expectancy and perceived treatment assessment

> “Baseline expectancy was measured in participants, and perceived treatment was recorded for both participants and central raters”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.3-8"></a>

###### Standalone drug effect without psychotherapy

> “The design of the MM120 ODT Phase 3 clinical program directly builds on the robust Phase 2b study results and incorporates best-in-class methodologies to mitigate the impact of functional unblinding, including the use of independent central raters blinded to both treatment assignment and visit number. The studies have also been designed to isolate the standalone drug effect of MM120 ODT from other psychotherapeutic intervention and follow industry best practices for safety monitoring.”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.1.3-9"></a>

###### Adaptive design: blinded interim sample size re-estimation

> “Both trials use an adaptive trial design with a blinded interim sample size re-estimation (“SSRE”), allowing for an increase in sample size by up to 50% in each trial depending on the observed values for certain nuisance parameters.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-3.1.1.3-10"></a>

###### Part B: symptom-triggered open-label treatment

> “Open-label treatment in Part B was based on prespecified symptom severity, which allowed for assessment of retreatment patterns and durability of response in a real-world fashion (Figure 2)”
> “To maintain data integrity, participants who met retreatment thresholds and had no safety concerns were required to re-treat”
> “Total of up to 5 doses over 52-week period with final dose no later than week 50.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.3-11"></a>

###### Part B: follow-up observation and retreatment threshold

> “GAD-7 (ePRO): biweekly”
> “HAM-A (central rater): monthly or when GAD-7 ≥10”
> “Eligible for open-label treatment if HAM-A ≥16”
> “Up to 4 open-label doses of DT120 ODT 100 µg”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria: registry record

> “Diagnosis of GAD per DSM-5”
> “Male or female aged 18 to 74”
> “HAM-A Total Score ≥20”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion criteria: registry record

> “Certain psychiatric disorders (other than generalized anxiety disorder)”
> “First degree relative with or lifetime history of a psychotic disorder or bipolar disorder”
> “Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)”
> “Any clinically significant unstable illness”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.4-3"></a>

###### Diagnosis confirmed by the Mini-International Neuropsychiatric Interview

> “with a DSM-5-confirmed diagnosis of GAD, based on clinical assessment and the Mini-International Neuropsychiatric Interview (MINI), and a Hamilton Anxiety Rating Scale (HAM-A) total score of at least 20 at screening and baseline”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.4-4"></a>

###### Key inclusion criteria: Voyage and Panorama

> “GAD diagnosis based on DSM-5 and confirmed by MINI”
> “HAM-A total score ≥20 at screening and baseline”
> “MADRS items 1, 7, and 8 score ≤3 at screening and baseline”
> “Use of highly effective methods of contraception”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.4-5"></a>

###### Key exclusion criteria: Voyage and Panorama

> “Contraindicated medical or psychiatric conditions”
> “Systematic psychotherapy ≤4 weeks prior to screening or plans to initiate therapy”
> “Use of prohibited concomitant medications, supplements, or other therapeutics”
> “>10 instances of psychedelics use in the past 5 years and any use in the past 2 years”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.4-6"></a>

###### Prior psychedelic use criterion amended to any lifetime use

> “Exclusion criteria related to prior use of psychedelics was later amended to any lifetime use of psychedelics based on FDA feedback.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.4-7"></a>

###### Concomitant medications with interaction potential or anxiolytic or antidepressant effects

> “Participants were excluded if they had medical or psychiatric conditions that were contraindicated, or if they were taking concomitant medications, supplements, or other therapeutics with potential drug–drug interactions or anxiolytic or antidepressant effects that could not be discontinued”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.4-8"></a>

###### Independent review of eligibility

> “Eligibility criteria were reviewed independently by site personnel, central raters, and medical monitors, thereby enhancing diagnostic accuracy and reducing site-level variability (Table 1)”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arms: DT120 100 µg or placebo

> “Placebo Comparator: Arm 1 - Placebo”
> “Experimental: Arm 2 - 100µg DT120”
> “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.5-2"></a>

###### Single administration of DT120 ODT 100 µg in Part A

> “Of these, 214 participants were randomized 1:1 to receive a single administration of 100 µg of DT120 (n = 107) or placebo (n = 107; Table 1)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.5-3"></a>

###### Open-label doses in Part B

> “40-week extension with opportunity for open-label DT120 100 µg based on protocol-defined symptom and safety criteria; up to 4 Part B doses (max 5 total doses over 52 weeks)”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.5-4"></a>

###### Dosing session monitors and psychotherapy

> “Two qualified and trained DSMs monitored dosing, with the second DSM having the option to monitor remotely via video. A total of 3 DSMs were onsite, and a licensed HCP was available or on call ≤15 minutes from the site”
> “Psychotherapy was prohibited during dosing sessions. Standardized EoSC was used to assess participant status and ability to end the dosing session”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.5-5"></a>

###### End-of-session checklist: hourly from hour 5 after dosing

> “On the day of dosing, participants were assessed hourly beginning at hour 5 post-dose on a structured end-of-session checklist (EoSC).”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The EoSC is an 8-question checklist used to assess participant readiness for completion of monitoring after receiving DT120.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.5-6"></a>

###### Required monitoring period in the pivotal studies: 8 hours

> “Required monitoring period for all participants in pivotal studies is 8 hours and requires that participants clear the End of Session Checklist.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Hamilton Anxiety Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint: change in HAM-A total score at Week 12

> “The primary endpoint is change from baseline in HAM-A total score at Week 12. Key secondary multiplicity-controlled endpoints are change from baseline in Clinical Global Impression-Severity (CGI-S) scale score at Week 12, change from baseline in HAM-A total score at Week 1, and change from baseline in CGI-S score at Day 2.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.6.1-2"></a>

###### Week 12 timepoint based on the durability observed in the phase 2b study

> “The primary endpoint of Voyage will measure the change from baseline in HAM-A at Week 12, which is consistent with the durable clinical effect observed in the Phase 2b study.”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.1.6.1-3"></a>

###### HAM-A: 14-item clinician-rated scale, range 0 to 56

> “The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

> “The HAM-A is a 14-item clinician-rated outcome measure assessing various domains of anxiety with a range of 0–56.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.6.1-4"></a>

###### Minimal clinically important difference and dose selection from the phase 2b study

> “The minimal clinically important difference was 2.5 points.”
> “These findings support the selection of 100-µg dose of MM120 for pivotal trials to assess its efficacy, durability, and safety in the treatment of GAD.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.1.6.1-5"></a>

###### Secondary endpoints: HAM-A response, remission, and mild or better at Week 12

> “HAM-A response (≥50% improvement) at week 12”
> “HAM-A remission (total score ≤7) at week 12”
> “HAM-A mild or better (total score <16) at week 12”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.6.1-6"></a>

###### Clinical Global Impression-Severity: range 1 to 7

> “The CGI-S is a clinician-rated outcome measure assessing overall severity of illness with a range of 1 to 7.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.6.1-7"></a>

###### Registered secondary endpoints: patient-reported outcomes, functioning, and quality of life

> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)”
> “Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.6.1-8"></a>

###### Registered secondary endpoints: retreatment in Part B

> “Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period”
> “Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Enrolled: 214 participants randomized 1:1

> “Completed enrollment in Voyage (GAD) with 214 participants randomized 1:1 to receive DT120 ODT 100 µg or placebo.”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.1.7.1-2"></a>

###### Sample size re-estimation: no increase required

> “The SSRE for Voyage has been completed and it was determined that no increase in the sample size of the trial is required.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “The protocol-specified blinded sample size re-estimation is complete, requiring no increase in enrollment.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

<a id="topic-3.1.1.7.1-3"></a>

###### Analyzed: all randomized participants in the intention-to-treat population

| Arm | Randomized | Analysis population |
| --- | --- | --- |
| DT120 ODT | “n=107” | “100% included in ITT population” |
| Placebo ODT | “n=107” | “100% included in ITT population” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.1-4"></a>

###### Planned enrollment: approximately 200 participants, December 2024 to February 2026, superseded in May 2026

> “Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT versus placebo and is expected to enroll approximately 200 participants in the United States.”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

> “Voyage is expected to enroll approximately 200 participants in the U.S. randomized 1:1 to receive DT120 ODT 100 µg or placebo.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Primary analysis: mixed-effects model for repeated measures with reference-based imputation, ITT population

> “Primary endpoint of the study was change from baseline in HAM-A at week 12 using a mixed-effects model repeated-measures statistical analysis with reference-based imputation.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “Source: Voyage study documents. ITT population.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Multiplicity control: hierarchical testing of key secondary endpoints

> “Includes the primary endpoint and all hierarchically controlled key secondary endpoints.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Safety population: Part A through Week 12

> “Source: Voyage study documents. Safety population in study part A (through week 12).”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.2-4"></a>

###### Subgroup analyses: same model as the primary analysis

> “For each subgroup, the change from baseline in HAM-A total score is analyzed using the same MMRM model as the primary efficacy analysis. If the number of patients is small for a subgroup, the treatment difference will not be stable as it would be highly sensitive to outliers.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.2-5"></a>

###### Part B interim analysis: extension population and ITT Part A+B population

> “Extension population includes participants with at least one Part B visit completed.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

> “Based on interim analysis as of July 15, 2026.  ITT Part A+B population with treatment policy strategy.  Interim analysis based on partial data and subject to change.”
> “n is the number of participants in the ITT Part A+B population with non-missing HAM-A score at Baseline and the respective visit.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Screened and randomized

> “A total of 845 participants were screened for eligibility. Of these, 214 participants were randomized 1:1 to receive a single administration of 100 µg of DT120 (n = 107) or placebo (n = 107; Table 1)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.1-2"></a>

###### Part A completion

| Arm | Randomized | Completed Part A |
| --- | --- | --- |
| DT120 ODT | “n=107” | “90% completed Part A” |
| Placebo ODT | “n=107” | “88% completed Part A” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.1-3"></a>

###### Overall discontinuation: 10% and 12%

> “Overall discontinuation rates were similar between DT120 ODT 100 µg and placebo groups (10% and 12%).”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.1.8.1-4"></a>

###### Part B interim disposition as of July 15, 2026

| Part A arm | Part B extension population | Through Week 28 | Through Week 36 | Through Week 52 |
| --- | --- | --- | --- | --- |
| DT120 ODT | “n=90” | “Through Week 28 (n=44)” | “Through Week 36 (n=31)” | “Through Week 52 (n=14)” |
| Placebo ODT | “n=87” | “Through Week 28 (n=53)” | “Through Week 36 (n=30)” | “Through Week 52 (n=8)” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

> “Based on interim analysis as of July 15, 2026.  Interim analysis based on partial data and subject to change.”
> “Extension population includes participants with at least one Part B visit completed.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographics and baseline characteristics: ITT population

| Characteristic | DT120 ODT (n = 107) | Placebo ODT (n = 107) | Overall (N = 214) |
| --- | --- | --- | --- |
| Age, mean (range), years | “42 (21–72)” | “43 (20–67)” | “42 (20–72)” |
| Female, n (%) | “63 (59)” | “74 (69)” | “137 (64)” |
| Male, n (%) | “44 (41)” | “33 (31)” | “77 (36)” |
| White, n (%) | “78 (73)” | “77 (72)” | “155 (72)” |
| Black or African American, n (%) | “9 (8)” | “19 (18)” | “28 (13)” |
| Asian, n (%) | “8 (7)” | “9 (8)” | “17 (8)” |
| Baseline HAM-A score, mean (SD) | “28.4 (5.9)” | “27.4 (5.5)” | “27.9 (5.7)” |
| Moderate GAD (HAM-A <24), n (%) | “26 (24)” | “28 (26)” | “54 (25)” |
| Severe GAD (HAM-A ≥24), n (%) | “81 (76)” | “79 (74)” | “160 (75)” |
| Baseline CGI-S score, mean (SD) | “4.6 (0.6)” | “4.6 (0.6)” | “4.6 (0.6)” |
| Past use of any psychedelic, n (%) | “18 (17)” | “27 (25)” | “45 (21)” |
| Past LSD use, n (%) | “10 (9)” | “9 (8)” | “19 (9)” |
| No past GAD medications, n (%) | “35 (33)” | “36 (34)” | “71 (33)” |
| One past GAD medication, n (%) | “31 (29)” | “34 (32)” | “65 (30)” |
| Two or more past GAD medications, n (%) | “41 (38)” | “37 (35)” | “78 (36)” |
| Comorbid MDD, n (%) | “43 (40)” | “37 (35)” | “80 (37)” |
| Years since GAD diagnosis, mean (SD) | “11.1 (10.1)” | “12.9 (11.6)” | “12.0 (10.9)” |
| Years since onset of GAD symptoms, mean (SD) | “21.9 (13.7)” | “25.7 (14.4)” | “23.8 (14.1)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Severity categories and psychedelic definitions

> “Eligibility criteria required a baseline HAM-A score of ≥20; moderate symptoms are defined as a HAM-A score of 16–23.”
> “Psychedelics include LSD, psilocybin, dimethyltryptamine, and other classic serotonergic psychedelics.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Baseline MADRS score

| Characteristic | DT120 ODT (n=107) | Placebo ODT (n=107) | Overall (n=214) |
| --- | --- | --- | --- |
| MADRS score, mean (SD) | “13.6 (4.6)” | “13.5 (4.4)” | “13.5 (4.5)” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### Characteristics at Part B entry: interim analysis

| Characteristic | DT120 ODT in Part A (n=62) | Placebo ODT in Part A (n=75) | Total (n=137) |
| --- | --- | --- | --- |
| Mean age (years) | “40.9” | “43.6” | “42.3” |
| Sex, female (%) | “52%” | “68%” | “61%” |
| Race (% white) | “76%” | “76%” | “76%” |
| HAM-A score at Part B entry | “16.8” | “21.2” | “n/a” |
| CGI-S score at Part B entry | “3.6” | “4.2” | “n/a” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

> “ITT population who entered Part B. Data based on Week 12 in Part A.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary and key secondary endpoints: Part A

| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A: LS mean change at Week 12 (primary) | “-11.6” | “-6.2” | “-5.4 (p<.0001)” |
| CGI-S: LS mean change at Week 12 (key secondary) | “-1.0” | “-0.4” | “-0.6 (p<.0001)” |
| HAM-A: LS mean change at Week 1 (key secondary) | “-11.9” | “-4.2” | “-7.7 (p<.0001)” |
| CGI-S: LS mean change at Day 2 (key secondary) | “-1.0” | “-0.2” | “-0.8 (p<.0001)” |

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.8.3-2"></a>

###### Primary endpoint: effect size d=0.81

> “The Least Squares (LS) mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -11.6 compared with -6.2 for participants who received placebo, an LS mean difference of -5.4 points (p<0.0001), corresponding to a standardized effect size of d=0.81. Efficacy was rapid, with changes seen as early as Day 2 and sustained at all post-baseline timepoints in Part A.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.8.3-3"></a>

###### Response, remission, and mild or better at Week 12

| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A response rate (≥50%) at Week 12 | “43%” | “16%” | “27% (p<0.0001)” |
| HAM-A remission rate (≤7) at Week 12 | “14%” | “4%” | “10% (p=0.0222)” |
| HAM-A mild or better (<16) at Week 12 | “51%” | “23%” | “28% (p<0.0001)” |

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.8.3-4"></a>

###### HAM-A change from baseline by visit

| Visit | DT120 ODT: change from baseline | Improvement over placebo |
| --- | --- | --- |
| Week 1 | “Week 1: −11.9 points” | “Week 1: −7.7 points” |
| Week 4 | “Week 4: −12.5 points” | “Week 4: −6.8 points” |
| Week 8 | “Week 8: −12.1 points” | “Week 8: −5.5 points” |
| Week 12 | “Week 12: −11.6 points” | “Week 12: −5.4 points” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.3-5"></a>

###### CGI-S change from baseline by visit

| Visit | DT120 ODT: change from baseline | Improvement over placebo |
| --- | --- | --- |
| Day 2 | “Day 2: −1.0 points” | “Day 2: −0.8 points” |
| Week 1 | “Week 1: −1.4 points” | “Week 1: −1.1 points” |
| Week 4 | “Week 4: −1.3 points” | “Week 4: −0.7 points” |
| Week 8 | “Week 8: −1.1 points” | “Week 8: −0.6 points” |
| Week 12 | “Week 12: −1.0 points” | “Week 12: −0.6 points” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.3-6"></a>

###### Subgroup analyses: placebo-adjusted change in HAM-A at Week 12

| Subgroup | Placebo-adjusted change in LS mean (SE) |
| --- | --- |
| All participants | “−5.4 (1.0)” |
| Time since GAD symptoms began <22 years (n = 107) | “−5.9 (1.4)” |
| Time since GAD symptoms began ≥22 years (n = 107) | “−4.7 (1.5)” |
| Previous GAD medications <2 (n = 136) | “−4.2 (1.2)” |
| Previous GAD medications ≥2 (n = 78) | “−5.6 (1.7)” |
| Male (n = 77) | “−7.1 (1.7)” |
| Female (n = 137) | “−5.5 (1.2)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “The treatment effect was maintained across key subgroups, including in participants with ≥2 previous trials of medications for GAD (Figure 5)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.3-7"></a>

###### Part B interim: response, remission, and mild or better through Week 28 among participants given DT120 in Part A

| Visit | n | HAM-A improvement ≥50% | HAM-A ≤7 | HAM-A <16 |
| --- | --- | --- | --- | --- |
| Week 12 | “94” | “44%” | “14%” | “51%” |
| Week 16 | “62” | “31%” | “11%” | “45%” |
| Week 20 | “55” | “44%” | “13%” | “46%” |
| Week 24 | “41” | “51%” | “15%” | “61%” |
| Week 28 | “37” | “60%” | “24%” | “65%” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

> “Source: Voyage study documents. Based on interim analysis as of July 15, 2026.  ITT Part A+B population.  Interim analysis based on partial data and subject to change.”
> “Only includes participants who received DT120 ODT in Part A”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Adverse event overview: Part A safety population

| Adverse event | DT120 ODT (n = 107) | Placebo ODT (n = 107) |
| --- | --- | --- |
| Any TEAE, n (%) | “106 (99)” | “74 (69)” |
| Mild | “65 (61)” | “49 (46)” |
| Moderate | “41 (38)” | “24 (22)” |
| Severe | “0” | “1 (1)” |
| Any study drug–related TEAE, n (%) | “102 (95)” | “51 (48)” |
| Any AESI, n (%) | “100 (93)” | “30 (28)” |
| Any treatment-emergent SAE, n (%) | “0” | “3 (3)” |
| Any TEAE leading to discontinuation, n (%) | “1 (1)” | “0” |
| Any TEAE leading to death, n (%) | “0” | “0” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “AEs were collected in accordance with FDA final guidance for psychedelic drug development, which includes expected effects characterized as positive, favorable, or neutral.”
> “Severe AE was diverticulitis, occurring approximately 9 weeks after dose.”
> “Participant discontinued due to recurrence of depression approximately 6 weeks after dose.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.5-2"></a>

###### Adverse events of special interest: topline presentation value

| Adverse event | DT120 ODT (n=107) | Placebo ODT (n=107) |
| --- | --- | --- |
| Any Adverse Event of Special Interest (AESI) | “100 (94%)” | “30 (28%)” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.5-3"></a>

###### Severity, timing, and most common adverse events

> “DT120 was generally well tolerated. No serious adverse events (AEs), suicidal behavior, or self-injurious behavior were reported during Part A of the study”
> “All AEs reported for DT120 ODT were mild to moderate in severity (Table 2). The most common treatment-emergent AEs (TEAEs) were illusion, nausea, and euphoric mood. The majority of TEAEs occurred on the dosing day. The most common TEAE reported after the dosing day was headache”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “DT120 ODT 100 µg was generally well tolerated, with treatment-emergent adverse events (“TEAEs”) mild to moderate in severity, transient, and predominantly occurring on the day of dosing in Part A. No new safety signals were identified, including no suicidality signal or suicidal behavior. There were no drug-related serious adverse events in Part A.”
> “The overall TEAE rate for DT120 ODT 100 µg and placebo was 99% and 69%. The most common TEAEs (>10%) in the DT120 ODT 100 µg arm on dosing day were illusion (75%), nausea (38%), euphoric mood (26%) and headache (24%).”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.1.8.5-4"></a>

###### TEAEs with incidence of 10% or more, on the dosing day and after it

| TEAE | Dosing day: DT120 ODT (n=107) | Dosing day: placebo ODT (n=107) | After dosing day: DT120 ODT (n=107) | After dosing day: placebo ODT (n=107) |
| --- | --- | --- | --- | --- |
| Illusion | “80 (75%)” | “11 (10%)” | “2 (2%)” | “0” |
| Nausea | “41 (38%)” | “9 (8%)” | “3 (3%)” | “3 (3%)” |
| Euphoric mood | “28 (26%)” | “4 (4%)” | “0” | “0” |
| Headache | “26 (24%)” | “7 (7%)” | “12 (11%)” | “7 (7%)” |
| Feeling abnormal | “21 (20%)” | “3 (3%)” | “0” | “0” |
| Disorientation | “19 (18%)” | “2 (2%)” | “1 (1%)” | “0” |
| Dizziness | “14 (13%)” | “5 (5%)” | “1 (1%)” | “1 (1%)” |
| Crying | “13 (12%)” | “4 (4%)” | “0” | “0” |
| Thinking abnormal | “12 (11%)” | “1 (1%)” | “0” | “0” |
| Paraesthesia | “12 (11%)” | “4 (4%)” | “0” | “0” |
| Feeling of body temperature change | “12 (11%)” | “1 (1%)” | “0” | “0” |
| Anxiety | “11 (10%)” | “2 (2%)” | “3 (3%)” | “0” |
| Feeling of relaxation | “8 (8%)” | “12 (11%)” | “1 (1%)” | “0” |
| Hallucination, visual | “9 (8%)” | “2 (2%)” | “1 (1%)” | “0” |
| Insomnia | “7 (7%)” | “0” | “1 (1%)” | “6 (6%)” |
| Emotional disorder | “6 (6%)” | “1 (1%)” | “1 (1%)” | “0” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.5-5"></a>

###### Suicidality: Columbia-Suicide Severity Rating Scale

> “Participant suicidality assessment based on changes in C-SSRS.”
> “No suicidal or self-injurious behavior”
> “No indication of increased suicide-related risk”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.5-6"></a>

###### Serious adverse events across DT120 studies, including Part B of Voyage, as of September 14, 2026

> “As of September 14, 2026, a total of 14 participants reported a treatment emergent serious adverse event across all studies of DT120, including 1 SAE deemed treatment-related in Part B of Voyage, resulting in an SAE rate of approximately 1.45%”
> “Part B safety data are expected to be shared in a future presentation.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-3.1.1.8.5-7"></a>

###### Serious adverse events across DT120 studies, August 2026, superseded in November 2026

> “At the time of the analysis, a total of 13 participants reported a treatment emergent serious adverse event across all studies of DT120 ODT, including 1 SAE deemed treatment-emergent in Part B of Voyage, resulting in an SAE rate of approximately 1.7% across studies and populations.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.5-8"></a>

###### End-of-session checklist clearance: topline announcement, August 2026

> “The average time to meeting EoSC criteria was 6.4 hours for participants receiving DT120 ODT in Part A, with a median of 6.1 hours and 92% of participants meeting the EoSC criteria by hour 8.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.8.5-9"></a>

###### End-of-session checklist clearance: Psych Congress poster, September 2026

> “Average time to End-of-Session Checklist (EoSC) clearance was 6.4 hours (Figure 6). More than half of participants met all EoSC criteria at hour 6, and the majority of participants (90%) met all EoSC criteria by hour 8”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

- Publication status: results come from company topline announcements, presentations, and filings and from a report of the Voyage topline results; one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results.
- Functional unblinding: Voyage used a two-arm design of DT120 100 µg versus placebo without the 50 µg low-dose comparator used in Panorama. Study drug-related TEAEs occurred in 95% of participants receiving DT120 and 48% receiving placebo, and illusion occurred on the dosing day in 75% and 10%. Baseline expectancy and perceived treatment were recorded; the cited disclosures report no results of these assessments. Central HAM-A raters were blinded to treatment assignment and visit number. Past psychedelic use was reported by 21% of participants.
- Duration and dosing: the controlled comparison covers 12 weeks after a single dose. Part B is open label, and its results come from an interim analysis as of July 15, 2026, with 37 participants who received DT120 in Part A contributing HAM-A data at Week 28.
- Comparator: placebo was the only comparator; no active GAD treatment was included. The placebo group improved by 6.2 points on HAM-A at Week 12.
- Generalizability: participants were 18 to 74 years of age at approximately 35 sites in the United States, and people taking medications with anxiolytic or antidepressant effects that could not be discontinued, people with a personal or first-degree family history of psychotic or bipolar disorder, people with current alcohol or substance use disorder, and people in systematic psychotherapy within 4 weeks before screening were excluded.
- Outcomes not reported in the cited disclosures: registered patient-reported, functioning, quality of life (PGI-S, WPAI-SHP, EQ-5D-5L), and sexual functioning (CSFQ-14) endpoints. The sponsor stated that Part B safety data are expected to be shared in a future presentation.
- Discrepancies between sources: the share of participants clearing the end-of-session checklist by hour 8 is 92% in the topline announcement and 90% in the poster, and adverse events of special interest with DT120 are 100 (94%) in the topline presentation and 100 (93) in the poster.

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf); [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="heading-3.1.2"></a>

#### 3.1.2 Panorama

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Main objective in the EU trial record

> “Double-blind Period (Part A): To evaluate the efficacy of a single dose of 100 μg MM120 versus placebo on anxiety symptoms in adults with GAD”

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="topic-3.1.2.1-2"></a>

###### Registered study purpose and official title

> “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama”
> “A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.1-3"></a>

###### Objective stated by the sponsor

> “Panorama (MM120-301) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DT120 Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.1-4"></a>

###### Objectives of Part A and Part B across the phase 3 trials

> “Part A evaluated acute efficacy and safety over 12 weeks following a single administration of DT120”
> “Part B evaluated the maintenance of efficacy and safety and retreatment patterns over an additional 40 weeks”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates in the registry

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2025-01-29” |
| Primary completion (actual) | “2026-08-13” |
| Study completion (estimated) | “2027-05” |
| First posted | “2025-02-05” |
| Last update posted | “2026-09-04” |

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.2-2"></a>

###### Registered locations

> “This study has 36 locations”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.2-3"></a>

###### Registry status and results posting

> “Active, not recruiting”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.2-4"></a>

###### Study centers reported by the sponsor

> “Panorama enrolled 245 participants across approximately 32 study centers.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.2-5"></a>

###### Conduct in the United States and Europe

> “The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.2-6"></a>

###### EU member states and trial start

> “France, Poland, Germany, Czechia”
> “Start of trial 20/08/2025”

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="topic-3.1.2.2-7"></a>

###### EU member state decision, trial start, and recruitment dates

| Member state | Decision date | Trial start | Recruitment start | Recruitment end |
| --- | --- | --- | --- | --- |
| Germany | “19/02/2025” | “21/08/2025” | “04/09/2025” | “15/05/2026” |
| France | “20/02/2025” | “26/09/2025” | “22/12/2025” | “15/05/2026” |
| Czech Republic | “24/02/2025” | “20/08/2025” | “02/09/2025” | “15/05/2026” |
| Poland | “02/03/2025” | “25/09/2025” | “03/10/2025” | “15/05/2026” |

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="topic-3.1.2.2-8"></a>

###### EU estimated global end date

> “Estimated global end date of the trial:”
> “25/05/2027”

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="topic-3.1.2.2-9"></a>

###### First participant dosed, January 2025

> “today announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment generalized anxiety disorder (GAD).”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.2-10"></a>

###### Enrollment completion

> “Completed enrollment of Phase 3 Panorama study (GAD) with 245 participants randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo.”

Source: [Definium Therapeutics second quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/242/definium-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.2.2-11"></a>

###### Topline results of Part A reported September 14, 2026

> “On September 14, 2026, we announced that the Panorama study met its primary endpoint and all key secondary efficacy endpoints”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.2.2-12"></a>

###### Topline timing: September 2026, August 2026, superseded by results reported in September 2026

> “Panorama results anticipated September 2026”
> “Topline data anticipated in September 2026.”

Source: [Definium Therapeutics second quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/242/definium-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights)

> “With our Panorama topline results in GAD expected in September, we remain focused on bringing this potential new treatment to patients as quickly as possible.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.2-13"></a>

###### Topline timing: late third quarter of 2026, April 2026, superseded in August 2026

> “Topline data now anticipated in late 3Q 2026 (updated from 2H 2026).”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

> “Topline data expected in late 3Q 2026 (updated from 2H 2026).”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.2.2-14"></a>

###### Topline timing: second half of 2026, January 2025, superseded in April 2026

> “Topline data from the 12-week double-blind period anticipated in the second half of 2026”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

> “Topline data from the 12-week double-blind period (Part A) is anticipated in the second half of 2026.”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

> “Enrollment is on track in the Panorama study, the Company’s second Phase 3 study of MM120 ODT for the treatment of GAD.”
> “Topline data from the 12-week double-blind period (Part A) is anticipated in the second half of 2026.”

Source: [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

> “2H 2026: Topline data from Panorama – the second Phase 3 study of DT120 ODT in GAD”

Source: [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)

> “Panorama: study enrollment on track with topline data anticipated in 2H 2026.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “In January 2025, we announced the initiation of Panorama, with an anticipated topline readout (Part A results) in the second half of 2026.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 3 randomized, double-blind, placebo-controlled design with an open-label extension

> “The study consists of a 12-week double-blind treatment period (Part A) followed by a 40-week open-label extension (Part B), during which participants may be eligible to receive up to four additional doses of DT120 ODT 100 μg based on symptom severity, for a total study duration of approximately 56 weeks.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.3-2"></a>

###### Design aligned with Voyage

> “The clinical trial design of the 52-week Panorama study is aligned to Voyage and will be conducted in two parts: Part A, a 12-week, randomized, double-blind, placebo-controlled, parallel-group period; and Part B, a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT based on symptom severity.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.3-3"></a>

###### Randomization ratio and the 50 µg arm

> “Eligible participants were randomized 2:1:2 to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo, with the 50 µg arm included to help mitigate functional unblinding.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The 50 µg arm serves to confound participants’ ability to accurately assess the dose condition to which they have been randomized. This approach builds on the MM120 Phase 2b study, which the Company believes demonstrated that the clinical activity of MM120 was not attributable to functional unblinding and aligns with FDA guidance regarding the use of complementary designs across our Phase 2 and 3 studies.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

> “Voyage and Emerge established a 2-arm framework of DT120 100 μg versus placebo to characterize target dose efficacy and safety. Panorama and Ascend added DT120 50 μg as a low-dose comparator, thereby creating a 3-arm framework to evaluate efficacy and safety as well as mitigate functional unblinding”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.3-4"></a>

###### Statistical comparisons limited to 100 µg versus placebo

> “Statistical analyses & endpoints only compare 100 µg vs placebo”
> “Panorama included a DT120 ODT 50 µg control arm (n=52) that was not designed or powered for statistical comparisons.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.3-5"></a>

###### Registry design fields

| Field | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Triple” |
| Phase | “Phase 3” |
| Arm 1 | “Placebo Comparator: Arm 1 - Placebo” |
| Arm 2 | “Sham Comparator: Arm 2 - 50µg DT120” |
| Arm 3 | “Experimental: Arm 3 - 100µg DT120” |

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.3-6"></a>

###### Adaptive design with blinded sample size re-estimation

> “Both trials use an adaptive trial design with a blinded interim SSRE, allowing for an increase in sample size by up to 50% in each trial depending on the observed values for certain nuisance parameters.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-3.1.2.3-7"></a>

###### Blinding, central raters, and dosing session monitors

> “Participants, DSMs, central raters, and dosing sites were blinded to treatment and primary endpoint data”
> “HAM-A (GAD) or MADRS (MDD) central raters were independent from the dosing site and blinded to treatment and visit number”
> “Site raters could not serve as the DSM or HCP for the same participant after the screening or baseline assessments to mitigate functional unblinding”
> “Baseline expectancy was measured in participants, and perceived treatment was recorded for both participants and central raters”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “In Panorama, HAM-A ratings were assessed by central raters blinded to both treatment assignment and visit number.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.3-8"></a>

###### Symptom-triggered open-label treatment in Part B

> “Open-label treatment in Part B was based on prespecified symptom severity, which allowed for assessment of retreatment patterns and durability of response in a real-world fashion”
> “To maintain data integrity, participants who met retreatment thresholds and had no safety concerns were required to re-treat”
> “Total of up to 5 doses over 52-week period with final dose no later than week 50.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “GAD-7 (ePRO): biweekly”
> “HAM-A (central rater): monthly or when GAD-7 ≥ 10”
> “Eligible for open-label treatment if HAM-A ≥ 16”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Population enrolled

> “The study enrolled participants 18 to 74 years of age with a DSM-5-confirmed primary diagnosis of GAD and a minimum Hamilton Anxiety Rating Scale (HAM-A) total score of 20 at screening and baseline.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.4-2"></a>

###### Registered inclusion and exclusion criteria

> “Diagnosis of GAD per DSM-5”
> “Male or female aged 18 to 74”
> “HAM-A Total Score ≥20”
> “Certain psychiatric disorders (other than generalized anxiety disorder)”
> “First degree relative with or lifetime history of a psychotic disorder or bipolar disorder”
> “Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)”
> “Any clinically significant unstable illness”
> “without clinically relevant medical or psychiatric history”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.4-3"></a>

###### Key inclusion and exclusion criteria for Voyage and Panorama

| Criterion type | Criterion |
| --- | --- |
| Inclusion | “Age 18–74 years” |
| Inclusion | “GAD diagnosis based on DSM-5 and confirmed by MINI” |
| Inclusion | “HAM-A total score ≥20 at screening and baseline” |
| Inclusion | “MADRS items 1, 7, and 8 score ≤3 at screening and baseline” |
| Inclusion | “Use of highly effective methods of contraception” |
| Exclusion | “Contraindicated medical or psychiatric conditions” |
| Exclusion | “Systematic psychotherapy ≤4 weeks prior to screening or plans to initiate therapy” |
| Exclusion | “Use of prohibited concomitant medications, supplements, or other therapeutics” |
| Exclusion | “>10 instances of psychedelics use in the past 5 years and any use in the past 2 years” |

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.4-4"></a>

###### Amendment of the prior psychedelic use criterion

> “Exclusion criteria related to prior use of psychedelics was later amended to any lifetime use of psychedelics based on FDA feedback.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.4-5"></a>

###### Independent confirmation of eligibility

> “Eligibility criteria were reviewed independently by site personnel, central raters, and medical monitors, thereby enhancing diagnostic accuracy and reducing site-level variability”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.4-6"></a>

###### Exclusion of a current major depressive episode

> “Eligibility criteria excluded participants currently in a major depressive episode.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.4-7"></a>

###### Age range in the EU trial record

> “18-64 years, 65+ years”

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Study drug and placebo in the registry

> “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)”
> “lysergide tartrate”
> “LSD D-Tartrate”
> “A substance that is designed to have no therapeutic value”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.5-2"></a>

###### Single dose in Part A

| Arm | Part A treatment |
| --- | --- |
| DT120 ODT 100 µg | “DT120 ODT 100 µg” |
| DT120 ODT 50 µg | “DT120 ODT 50 µg control” |
| Placebo | “Placebo” |
| Dosing in Part A | “Single Dose” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.5-3"></a>

###### Open-label DT120 ODT 100 µg in Part B

> “40-week extension with opportunity for open-label DT120 100 µg based on protocol-defined symptom and safety criteria; up to 4 Part B doses (max 5 total doses over 52 weeks)”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.5-4"></a>

###### Dosing session monitoring and end-of-session checklist

> “Participants were monitored for a minimum of 8 hours on dosing day and were assessed hourly beginning 5 hours after dosing on a structured end-of-session checklist (EoSC).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Two qualified and trained DSMs monitored dosing, with the second DSM having the option to monitor remotely via video.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.5-5"></a>

###### No psychotherapy

> “Psychotherapy was prohibited during dosing sessions. Standardized EoSC was used to assess participant status and ability to end the dosing session”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “No psychotherapeutic intervention beyond study drug”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Hamilton Anxiety Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint and sponsor rationale for Week 12

> “The primary endpoint of Panorama will measure the change from baseline in HAM-A at Week 12 between MM120 ODT 100 µg and placebo, which is consistent with the durable clinical effect observed in the MM120 Phase 2b study.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.6.1-2"></a>

###### Registered primary outcome and HAM-A scoring

> “Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12”
> “The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

> “The HAM-A is a 14-item clinician-rated outcome measure assessing various domains of anxiety with a range of 0-56.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.6.1-3"></a>

###### FDA guidance on a 12-week double-blind endpoint and blinded central raters

> “Before an initial application for a product intended for the treatment of a chronic illness such as post-traumatic stress disorder or major depressive disorder, sponsors should evaluate with a double-blind design the effect of treatment at 12 weeks.”
> “Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.”
> “Sponsors should incorporate the use of central raters blinded to treatment allocation and visit number.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.2.6.1-4"></a>

###### Minimal clinically important difference used in the phase 2b trial

> “The minimal clinically important difference was 2.5 points.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.2.6.1-5"></a>

###### Sponsor target product profile for the HAM-A difference

> “Dashed line represents target product profile: durable efficacy of 4 points or greater”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.6.1-6"></a>

###### Key secondary multiplicity-controlled endpoints

> “The primary endpoint is change from baseline in HAM-A total score at Week 12. Key secondary multiplicity-controlled endpoints are change from baseline in Clinical Global Impression-Severity (CGI-S) scale score at Week 12, change from baseline in HAM-A total score at Week 1, and change from baseline in CGI-S score at Day 2.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The CGI-S is a clinician-rated outcome measure assessing overall severity of illness with a range of 1 to 7.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.6.1-7"></a>

###### Other registered secondary outcomes in Part A

> “HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period”
> “HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period”
> “Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)”
> “Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.6.1-8"></a>

###### Registered secondary outcomes in Part B

> “Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period”
> “Time to first treatment or lack of efficacy in the open-label period (Part B)”
> “Need for DT120 treatment as assessed by the average number of DT120 treatments during the study”
> “HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period”
> “HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Participants randomized

> “Panorama enrolled 245 participants across approximately 32 study centers.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

| Group | Participants randomized |
| --- | --- |
| DT120 ODT 100 µg | “n=96” |
| DT120 ODT 50 µg control | “n=52” |
| Placebo ODT | “n=97” |
| Total | “n=245” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.1-2"></a>

###### Enrollment in the registry

| Field | Registry record |
| --- | --- |
| Enrollment (actual) | “245” |
| Planned maximum in the detailed description | “The study will enroll up to 375 participants aged 18 to 74 years” |

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants analyzed in the ITT and safety populations

> “Safety population (n=244)”
> “ITT population (n=245)”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.1-4"></a>

###### Planned enrollment: target of 200 participants after blinded sample size re-estimation, April 2026, superseded in August 2026

> “Panorama: Blinded sample size re-estimation complete with total target enrollment updated to 200 participants. Current enrollment over 200 participants and screening now closed.”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

> “Completed the blinded sample size re-estimation for Panorama (GAD) with total target enrollment updated to 200 participants. Current enrollment is over 200 participants, and screening has been closed.”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.2.7.1-5"></a>

###### Planned enrollment: approximately 250 participants, January 2025, superseded in April 2026

> “The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

> “Panorama is expected to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 µg, MM120 ODT 50 µg or placebo) in the U.S. and Europe.”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

> “Panorama is expected to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 µg, MM120 ODT 50 µg control, or placebo) in the U.S. and Europe.”

Source: [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

> “Panorama is expected to enroll approximately 250 participants, in the U.S. and Europe, randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “Panorama is anticipated to enroll approximately 250 participants (randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg or placebo).”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Primary analysis population and model

> “Primary endpoint of the study was change in HAM-A at week 12 between 100 µg and placebo using a Mixed-Effects Model Repeated Measures (MMRM) statistical analysis with reference-based imputation.”
> “ITT population. Placebo-adjusted HAM-A at week 12 using a Mixed-Effects Model Repeated Measures (MMRM) statistical analysis with reference-based imputation.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-2"></a>

###### Multiplicity control of key secondary endpoints

> “Includes the primary endpoint and all hierarchically controlled key secondary endpoints.”
> “Key secondary endpoints of the study was change in CGI-S at day 2 and week 12 between 100 µg and placebo using a Mixed-Effects Model Repeated Measures (MMRM) statistical analysis with reference-based imputation.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Response and remission analyses

> “ITT population. Pre-planned secondary endpoints.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-4"></a>

###### Safety population

> “Safety population in study part A (through week 12).”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-5"></a>

###### Subgroup analyses

> “Subgroup analysis of ITT population; 100 µg and placebo groups only.”
> “For each subgroup, the change from baseline in HAM-A total score is analyzed using the same MMRM model as the primary efficacy analysis. If the number of patients is small for a subgroup, the treatment difference will not be stable as it would be highly sensitive to outliers.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-6"></a>

###### Part B interim analysis populations

> “Based on interim analysis as of August 11, 2026. Interim analysis based on partial data and subject to change.”
> “ITT population who entered Part B. Data based on Week 12 in Part A.”
> “ITT Part A+B population with treatment policy strategy.”
> “50 µg cohort not included due to small n.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Part A disposition

| Group | Randomized | ITT population | Completed Part A |
| --- | --- | --- | --- |
| DT120 ODT 100 µg | “n=96” | “100% included in ITT population” | “90% completed Part A” |
| DT120 ODT 50 µg control | “n=52” | “100% included in ITT population” | “87% completed Part A” |
| Placebo ODT | “n=97” | “100% included in ITT population” | “90% completed Part A” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.1-2"></a>

###### Overall discontinuation in Part A

> “Overall discontinuation rates were similar between DT120 ODT 100 μg, DT120 50 μg, and placebo groups (10.4%, 11.5%, and 10.3%).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.8.1-3"></a>

###### Part B disposition at the interim analysis of August 11, 2026

| Part A group | Entered Part B | Through Week 28 | Through Week 36 | Through Week 52 |
| --- | --- | --- | --- | --- |
| DT120 ODT 100 µg | “n=76” | “Through Week 28 (n=35)” | “Through Week 36 (n=24)” | “Through Week 52 (n=8)” |
| DT120 ODT 50 µg control | “n=42” | “Through Week 28 (n=19)” | “Through Week 36 (n=10)” | “Through Week 52 (n=3)” |
| Placebo ODT | “n=86” | “Through Week 28 (n=43)” | “Through Week 36 (n=35)” | “Through Week 52 (n=14)” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.1-4"></a>

###### Part B enrollment in the extension population

| Part A group | Participants |
| --- | --- |
| DT120 ODT 100 µg | “n=62” |
| DT120 ODT 50 µg control | “n=33” |
| Placebo ODT | “n=68” |
| Total | “n=163” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline HAM-A score

> “The mean baseline HAM-A score at study entry was 28.3 in the DT120 ODT 100 µg treatment group (n=96) and 28.0 in the placebo group (n=97).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.8.2-2"></a>

###### Demographics and baseline characteristics, ITT population

| Characteristic | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=52) | Placebo ODT (n=97) | Overall (n=245) |
| --- | --- | --- | --- | --- |
| Mean age (years) | “39.8” | “40.4” | “42.3” | “40.9” |
| Sex (% female) | “62%” | “56%” | “62%” | “60%” |
| Race (% white) | “82%” | “85%” | “84%” | “83%” |
| Baseline HAM-A score, mean (SD) | “28.3 (5.5)” | “27.7 (4.8)” | “28.0 (5.6)” | “28.0 (5.4)” |
| Baseline CGI-S score, mean (SD) | “4.7 (0.5)” | “4.7 (0.6)” | “4.7 (0.6)” | “4.7 (0.6)” |
| Past use of any psychedelic, n (%) | “11 (12%)” | “8 (15%)” | “16 (17%)” | “35 (14%)” |
| Past use of LSD, n (%) | “4 (4%)” | “4 (8%)” | “8 (8%)” | “16 (7%)” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.2-3"></a>

###### Disease severity, treatment history, and comorbidity, ITT population

| Characteristic | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=52) | Placebo ODT (n=97) | Overall (n=245) |
| --- | --- | --- | --- | --- |
| HAM-A moderate (<24), n (%) | “20 (21%)” | “9 (17%)” | “27 (28%)” | “56 (23%)” |
| HAM-A severe (≥24), n (%) | “76 (79%)” | “43 (83%)” | “70 (72%)” | “189 (77%)” |
| No past GAD treatments, n (%) | “29 (30%)” | “14 (27%)” | “17 (18%)” | “60 (25%)” |
| One past GAD treatment, n (%) | “20 (21%)” | “15 (29%)” | “22 (23%)” | “57 (23%)” |
| Two or more past GAD treatments, n (%) | “47 (49%)” | “23 (44%)” | “58 (60%)” | “128 (52%)” |
| Comorbid MDD, n (%) | “28 (29%)” | “17 (33%)” | “25 (26%)” | “70 (29%)” |
| MADRS score, mean (SD) | “13.3 (4.4)” | “13.4 (4.5)” | “13.5 (3.9)” | “13.4 (4.2)” |
| Years since diagnosis of GAD, mean (SD) | “6.9 (7.6)” | “9.4 (11.4)” | “9.9 (8.8)” | “8.6 (9.0)” |
| Years since onset of GAD symptoms, mean (SD) | “16.4 (12.6)” | “18.2 (15.5)” | “19.1 (13.4)” | “17.8 (13.6)” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.2-4"></a>

###### Characteristics at Part B entry

| Characteristic | DT120 ODT 100 µg (n=62) | DT120 ODT 50 µg control (n=33) | Placebo ODT (n=68) | Total (n=163) |
| --- | --- | --- | --- | --- |
| Mean age (years) | “39.5” | “42.3” | “42.8” | “41.4” |
| Sex, female (%) | “62.9%” | “51.5%” | “58.8%” | “58.9%” |
| Race (% white) | “82.3%” | “87.9%” | “83.8%” | “84.0%” |
| HAM-A score at Part B entry | “18.3” | “21.6” | “23.3” | “21.1” |
| CGI-S score at Part B entry | “3.7” | “4.0” | “4.2” | “4.0” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary endpoint: change in HAM-A total score at Week 12

> “The Least Squares (LS) mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -9.8 compared with -4.7 for participants who received placebo, an LS mean difference of -5.1 points (p<0.0001), corresponding to a standardized effect size of d=0.64. Efficacy was rapid, with changes seen as early as Day 2 and sustained at all post-baseline timepoints in Part A.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The LS mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -9.8 compared with -4.7 for participants who received placebo, an LS mean difference of -5.1 points (p<0.0001), corresponding to a standardized effect size of d=0.64.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary, key secondary, and other secondary endpoints

| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A: LS mean change at Week 12 (primary) | “-9.8” | “-4.7” | “-5.1 (p<0.0001)” |
| CGI-S: LS mean change at Week 12 (key secondary) | “-1.0” | “-0.5” | “-0.6 (p<0.0001)” |
| HAM-A: LS mean change at Week 1 (key secondary) | “-9.8” | “-4.5” | “-5.3 (p<0.0001)” |
| CGI-S: LS mean change at Day 2 (key secondary) | “-1.1” | “-0.3” | “-0.8 (p<0.0001)” |
| HAM-A response rate (≥50%) at Week 12 | “32%” | “14%” | “18% (p<0.05)” |
| HAM-A remission rate (≤7) at Week 12 | “15%” | “4%” | “12% (p<0.05)” |
| HAM-A mild or better (<16) at Week 12 | “35%” | “17%” | “19% (p<0.01)” |

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Calculated differences may not equal the arithmetic differences between displayed values due to rounding.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.8.3-3"></a>

###### HAM-A change by visit, 100 µg and 50 µg arms

| Visit | 100 µg: change from baseline | 50 µg: change from baseline | 100 µg: improvement over placebo | 50 µg: improvement over placebo |
| --- | --- | --- | --- | --- |
| Week 1 | “-9.8” | “-10.3” | “-5.3” | “-5.8” |
| Week 4 | “-12.3” | “-8.8” | “-7.0” | “-3.5” |
| Week 8 | “-10.4” | “-8.1” | “-5.3” | “-3.0” |
| Week 12 | “-9.8” | “-8.3” | “-5.1” | “-3.6” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-4"></a>

###### CGI-S change by visit, 100 µg and 50 µg arms

| Visit | 100 µg: change from baseline | 50 µg: change from baseline | 100 µg: improvement over placebo | 50 µg: improvement over placebo |
| --- | --- | --- | --- | --- |
| Day 2 | “-1.1” | “-1.1” | “-0.8” | “-0.8” |
| Week 1 | “-1.2” | “-1.3” | “-0.7” | “-0.8” |
| Week 4 | “-1.4” | “-1.2” | “-1.0” | “-0.7” |
| Week 12 | “-1.1” | “-0.9” | “-0.6” | “-0.4” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-5"></a>

###### Odds ratios for response, remission, and mild or better at Week 12

| Outcome at Week 12 | Odds ratio, DT120 ODT 100 µg vs placebo |
| --- | --- |
| Response (HAM-A ≥ 50% improvement) | “Odds ratio: 2.9” |
| Remission (HAM-A ≤ 7) | “Odds ratio: 4.2” |
| Mild or better (HAM-A < 16) | “Odds ratio: 2.6” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-6"></a>

###### DT120 ODT 50 µg control arm

> “Panorama included a DT120 ODT 50 µg control arm (n=52) that was not designed or powered for statistical comparisons. Consistent with the dose-response profile demonstrated in our Phase 2b trial, DT120 ODT 50 µg demonstrated a placebo-adjusted change of -3.5 and -3.6 at Weeks 4 and 12, approximately 50% and 29% lower than was observed for DT120 ODT 100 µg.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.8.3-7"></a>

###### Treatment guess and functional unblinding

> “91% and 95% of participants at 50 and 100 µg correctly guessed assignment to drug”
> “Results support the conclusion that DT120 dose response is not attributable to functional unblinding”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-8"></a>

###### Subgroups analyzed for HAM-A change at Week 12

> “Treatment Effect Maintained Across Key Subgroups”
> “Less than two (n=88)”
> “Two or more (n=105)”
> “Male (n=74)”
> “Female (n=119)”
> “<22 yrs (n=135)”
> “>22 yrs (n=58)”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-9"></a>

###### Pooled standard deviation of the primary endpoint

| Item | Panorama |
| --- | --- |
| Primary endpoint, DT120 vs placebo | “-5.1” |
| Design | “3 arms” |
| Baseline HAM-A | “28.0” |
| Baseline MADRS | “13.4” |
| Pooled endpoint SD | “8.4” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-10"></a>

###### Part B interim analysis: response, remission, and mild or better through Week 28

| Visit | Participants (n) | HAM-A improvement ≥ 50% | HAM-A ≤ 7 | HAM-A < 16 |
| --- | --- | --- | --- | --- |
| Week 12 | “87” | “32%” | “15%” | “36%” |
| Week 16 | “66” | “23%” | “12%” | “32%” |
| Week 20 | “49” | “51%” | “18%” | “53%” |
| Week 24 | “35” | “60%” | “34%” | “66%” |
| Week 28 | “27” | “48%” | “19%” | “59%” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

> “Based on interim analysis as of August 11, 2026. ITT Part A+B population. Interim analysis based on partial data and subject to change.”
> “Only includes participants who received DT120 ODT in Part A.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Patient-reported and functional outcomes registered for Part A

> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score”
> “The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.”
> “The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments.”
> “The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.8.4-2"></a>

###### Results of patient-reported outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Overview of adverse events in Part A

| Adverse event | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=51) | Placebo ODT (n=97) |
| --- | --- | --- | --- |
| Any TEAE | “91 (95%)” | “49 (96%)” | “61 (63%)” |
| Mild | “51 (53%)” | “29 (57%)” | “30 (31%)” |
| Moderate | “39 (41%)” | “19 (37%)” | “29 (30%)” |
| Severe | “1 (1%)” | “1 (2%)” | “2 (2%)” |
| Any study drug-related TEAE | “90 (94%)” | “47 (92%)” | “34 (35%)” |
| Any adverse event of special interest (AESI) | “84 (88%)” | “43 (84%)” | “31 (32%)” |
| Any SAE | “2 (2%)” | “1 (2%)” | “1 (1%)” |
| Any treatment-related SAE | “0” | “0” | “0” |
| Any TEAE leading to discontinuation | “0” | “0” | “0” |
| Any TEAE leading to death | “0” | “0” | “0” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

> “All SAEs were deemed unrelated to the study drug.”
> “Adverse events were collected in accordance with FDA Final Guidance for Psychedelic Drug Development, which includes expected effects characterized as positive, favorable, or neutral.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-2"></a>

###### Tolerability summary and overall TEAE rates

> “DT120 ODT 100 μg was generally well tolerated, with most treatment-emergent adverse events (TEAEs) mild to moderate in severity, transient, and predominantly occurring on the day of dosing. No new safety signals were identified, including no suicidality signal or suicidal behavior. There were no drug-related serious adverse events.”
> “The overall TEAE rate for DT120 ODT 100 μg, DT120 50 μg, and placebo was 94.8%, 96.1%, and 62.9%. The most common TEAEs (>10%) in the DT120 ODT 100 μg and 50 μg arms on dosing day were illusion (68%, 61%), nausea (37%, 26%), and headache (24%, 28%).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “There were no drug-related serious adverse events in Part A.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.2.8.5-3"></a>

###### TEAEs with incidence of 10% or more in the 100 µg arm, on and after dosing day

| TEAE | Dosing day: 100 µg (n=96) | Dosing day: 50 µg (n=51) | Dosing day: placebo (n=97) | After dosing day: 100 µg (n=96) | After dosing day: 50 µg (n=51) | After dosing day: placebo (n=97) |
| --- | --- | --- | --- | --- | --- | --- |
| Illusion | “65 (68%)” | “31 (61%)” | “12 (12%)” | “3 (3%)” | “0” | “0” |
| Nausea | “35 (37%)” | “13 (26%)” | “4 (4%)” | “2 (2%)” | “4 (8%)” | “1 (1%)” |
| Headache | “23 (24%)” | “14 (28%)” | “13 (13%)” | “13 (14%)” | “6 (12%)” | “10 (10%)” |
| Euphoric mood | “30 (31%)” | “16 (31%)” | “5 (5%)” | “1 (1%)” | “0” | “0” |
| Fatigue | “22 (23%)” | “5 (10%)” | “6 (6%)” | “7 (7%)” | “1 (2%)” | “4 (4%)” |
| Dizziness | “22 (23%)” | “10 (20%)” | “3 (3%)” | “1 (1%)” | “1 (2%)” | “0” |
| Anxiety | “16 (17%)” | “7 (14%)” | “7 (7%)” | “6 (6%)” | “3 (6%)” | “5 (5%)” |
| Crying | “20 (21%)” | “6 (12%)” | “0” | “0” | “1 (2%)” | “0” |
| Feeling cold | “14 (15%)” | “2 (4%)” | “6 (6%)” | “0” | “0” | “1 (1%)” |
| Paraesthesia | “13 (14%)” | “4 (8%)” | “3 (3%)” | “0” | “1 (2%)” | “1 (1%)” |
| Time perception altered | “13 (14%)” | “4 (8%)” | “1 (1%)” | “0” | “0” | “0” |
| Feeling of relaxation | “12 (13%)” | “8 (16%)” | “11 (11%)” | “1 (1%)” | “0” | “0” |
| Inappropriate affect | “12 (13%)” | “4 (8%)” | “0” | “0” | “0” | “0” |
| Feeling hot | “11 (12%)” | “4 (8%)” | “4 (4%)” | “0” | “0” | “0” |
| Emotional disorder | “8 (8%)” | “3 (6%)” | “3 (3%)” | “3 (3%)” | “0” | “0” |
| Feeling abnormal | “10 (10%)” | “7 (14%)” | “4 (4%)” | “0” | “0” | “1 (1%)” |
| Restlessness | “10 (10%)” | “1 (2%)” | “3 (3%)” | “1 (1%)” | “0” | “1 (1%)” |
| Tremor | “10 (10%)” | “4 (8%)” | “1 (1%)” | “1 (1%)” | “0” | “0” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-4"></a>

###### Mechanism-based adverse event categories

| Category | DT120 ODT 100 µg | DT120 ODT 50 µg |
| --- | --- | --- |
| Perceptual changes | “87%” | “78%” |
| Affective changes | “66%” | “65%” |
| Behavioral changes | “18%” | “4%” |
| Changes in thinking | “27%” | “35%” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

> “Mechanism-based adverse event rates based on number of participants experiencing in Part A; safety population.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-5"></a>

###### Suicidality

> “No suicidal or self-injurious behavior”
> “No indication of increased suicide-related risk”
> “Participant suicidality assessment based on changes in C-SSRS.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-6"></a>

###### Time to meet end-of-session checklist criteria

> “The average time to meet EoSC criteria was 6.2 hours for participants receiving DT120 ODT 100 μg, with a median of 6.0 hours and 94% of participants meeting EoSC criteria by hour 8. Across over 1,000 treatment sessions in the Phase 3 program through September 10, 2026, 97% of participants met EoSC criteria by hour 8.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

| Hour after dosing | Panorama, Part A (n=96) | All phase 3 studies (n=1,061 sessions) |
| --- | --- | --- |
| Hour 5 | “45%” | “48%” |
| Hour 6 | “66%” | “66%” |
| Hour 7 | “88%” | “87%” |
| Hour 8 | “94%” | “97%” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-7"></a>

###### Safety in Part B

> “Part B safety data are expected to be shared in a future presentation.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

Panorama randomized 245 participants 2:1:2 to a single dose of DT120 ODT 100 µg (96), DT120 ODT 50 µg (52), or placebo (97), and its primary analysis compares the 100 µg arm with placebo only. The 50 µg arm was not designed or powered for statistical comparisons, so the placebo-adjusted changes of -3.5 at Week 4 and -3.6 at Week 12 in that arm, and the dose-response statements built on them, carry no hypothesis test. The primary endpoint difference of -5.1 points (d=0.64) exceeds the 2.5-point minimal clinically important difference used in the phase 2b trial and the sponsor's 4-point target product profile; in the presentation's comparison of its trials, Panorama had a pooled endpoint standard deviation of 8.4. The study had no active comparator.

The 50 µg arm was included to mitigate functional unblinding, yet 91% (50 µg) and 95% (100 µg) of participants correctly guessed assignment to drug; no placebo-arm guess rate was reported. HAM-A ratings were made by central raters blinded to treatment assignment and visit number, and FDA guidance states that functional unblinding can lead to expectation bias. The sponsor states that the results support the conclusion that the dose response is not attributable to functional unblinding.

The results come from sponsor topline disclosures (an announcement, a slide presentation, and a Form 10-Q), the registry record lists no results posted, and one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results. These disclosures report no confidence intervals for the primary or key secondary endpoints. Response, remission, and mild-or-better rates (32% vs 14%, 15% vs 4%, 35% vs 17%) are other secondary endpoints outside the multiplicity-controlled key secondary endpoints. Subgroup analyses cover the 100 µg and placebo arms only, and the presentation states that small subgroups give unstable estimates. Patient-reported, functional, quality of life, and sexual functioning outcomes (PGI-S, WPAI-SHP, EQ-5D-5L, CSFQ-14) are registered but unreported.

Part B results come from an interim analysis as of August 11, 2026, based on partial data and subject to change, with open-label dosing and declining numbers of participants (87 at Week 12 and 27 at Week 28 in the response analysis); the 50 µg cohort was excluded for small numbers. The presentation reports two Part B denominators, 204 participants entering Part B (76, 42, and 86 by Part A group) and an extension population of 163 (62, 33, and 68), without stating how they differ. The sponsor states that Part B safety data are expected in a future presentation.

The enrolled population was 60% female and 83% white, aged 18 to 74 years, excluded a current major depressive episode, substance use disorder, and psychotic or bipolar disorder in the participant or a first-degree relative, and excluded systematic psychotherapy within 4 weeks before screening. The psychedelic use exclusion was later amended to any lifetime use; 35 participants (14%) reported past use of any psychedelic and 16 (7%) past use of LSD. Treatment history differed between arms: 60% of placebo participants and 49% of 100 µg participants had two or more past GAD treatments. Enrollment exceeded the target of 200 participants set after a blinded sample size re-estimation. The company reports approximately 32 study centers while the registry lists 36 locations. Participants were monitored for at least 8 hours on dosing day, and 94% of the 100 µg arm met end-of-session checklist criteria by hour 8. The methods report states that Definium Therapeutics funded the study and that all of its authors are company employees.

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595); [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf); [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download); [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="topic-3.1.2.9-2"></a>

###### Functional unblinding in psychedelic trials

> “Functional unblinding can lead to expectation bias in the patients who experience perceptual disturbances, or in those who observe them, which may lead to an expectation that the participant will experience clinical benefit; alternatively, those who receive a placebo and do not experience or observe a perceptual change may expect that the participant will not benefit.”
> “Study results should be strongly persuasive and robust across study endpoints to overcome biases that may be introduced by functional unblinding.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.2.9-3"></a>

###### Interim status of Part B data

> “Based on interim analysis as of August 11, 2026. Interim analysis based on partial data and subject to change.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.9-4"></a>

###### Funding and authorship of the methods poster

> “The study was funded by Definium Therapeutics, Inc.”
> “All authors are employees of Definium Therapeutics, Inc.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

Additional sources: [Definium Therapeutics NEI Fall Congress announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/257/definium-therapeutics-presents-topline-phase-3-data-for-dt120-odt-in-generalized-anxiety-disorder-and-major-depressive-disorder-at-2026-nei-fall-congress)

<a id="heading-3.1.3"></a>

#### 3.1.3 MMED008

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Objective stated in the publication

> “To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD.”
> “The current phase 2b study assessed the dose response, efficacy, safety, and tolerability of a single treatment with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 vs placebo in participants with moderate to severe GAD.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.1-2"></a>

###### Primary, key secondary, and exploratory objectives in the protocol

> “To determine the dose-response signal and assess the dose-response relationship of 4 doses of MM-120 (25, 50, 100, or 200 μg freebase-equivalent) as measured by the change in HAM-A Total Score from Baseline to Week 4”
> “To determine the dose-response signal and assess the dose-response relationship of 4 doses of MM-120 (25, 50, 100, or 200 μg freebase-equivalent) as measured by the change in HAM-A Total Score from Baseline to Week 8”
> “To explore the effect of MM-120 on direct and indirect health-care resource utilization (HCRU) and associated costs”
> “To assess blind integrity and to examine whether guess rates are associated with outcomes such as AEs or mood/anxiety symptoms”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.1-3"></a>

###### Registered study purpose

> “This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.1-4"></a>

###### Sponsor statement of the primary and key secondary objectives

> “The study's main objective was to determine the dose-response relationship of four doses of MM120 versus placebo as measured by the change in HAM-A from Baseline to Week 4. The key secondary objective of the study was to determine the dose-response relationship of four doses of MM120 versus placebo as measured by the change in HAM-A from Baseline to Week 8.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates in the registry

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2022-08-24” |
| Primary completion (actual) | “2023-10-06” |
| Study completion (actual) | “2023-11-27” |
| First posted | “2022-06-07” |
| Results first posted | “2025-03-20” |

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.2-2"></a>

###### Registered locations

> “This study has 22 locations”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.2-3"></a>

###### Sites and conduct period reported in the publication

> “was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023.”
> “The last date of follow-up was November 27, 2023.”
> “The study was conducted at 22 outpatient psychiatric research sites across the US (eTable 2 in Supplement 3).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.2-4"></a>

###### First participant dosed, August 2022

> “today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of Generalized Anxiety Disorder (GAD).”

Source: [MindMed Phase 2b first patient dosed announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/29/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.2-5"></a>

###### Completion of enrollment, September 2023

> “announced today that it has completed enrollment and dosing in Study MMED008, the Company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.”

Source: [MindMed Phase 2b enrollment completion announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/125/mindmed-completes-enrollment-of-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.2-6"></a>

###### Number of clinical sites at completion of enrollment, September 2023, superseded in September 2025

> “198 participants dosed across 20 clinical sites”

Source: [MindMed Phase 2b enrollment completion announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/125/mindmed-completes-enrollment-of-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.2-7"></a>

###### Topline Week 4 results, December 2023

> “today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD).”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.2-8"></a>

###### Topline Week 12 results, March 2024

> “The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="topic-3.1.3.2-9"></a>

###### Journal publication, September 2025

> “Published Online: September 4, 2025.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Phase 2b randomized, double-blind, placebo-controlled, five-arm dose-finding design

> “In this phase 2b, multicenter, double-blind, placebo-controlled trial, participants with GAD were randomized equally to receive a single (freebase equivalent) treatment dose with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 or placebo without stratification (Figure 1).”
> “The study included 3 phases: (1) eligibility assessment (up to 35 days), (2) randomization (1 day), and (3) follow-up (12 weeks) (eFigure 1 in Supplement 3).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.3-2"></a>

###### Randomization and masking

> “Participants were equally randomized to 1 of 4 MM120 doses or placebo using a double-blind masking technique. Randomization was done centrally, using interactive response technology. All doses of MM120 and placebo were packaged identically.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.3-3"></a>

###### Protocol design and allocation ratio

> “This is a Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding clinical study that will assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) in comparison to placebo on anxiety symptoms in subjects diagnosed with GAD.”
> “Eligible subjects will be randomized in a 1:1:1:1:1 ratio to receive a single dose of either investigational drug (25, 50, 100 or 200 μg MM-120 freebase-equivalent) or placebo in a controlled clinical setting, which will be administered during the Dosing Session (Visit 3B) on Day 1.”
> “After Day 1/Randomization & Dosing Session (Visits 3A & 3B), subjects will have scheduled visits on Day 2 (Visit 4), Week 1 (Visit 5), Week 2 (Visit 6), Week 4 (Visit 7), Week 8 (Visit 8) and Week 12 (Visit 9).”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.3-4"></a>

###### Registry design fields

| Field | Registry record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Phase | “Phase 2” |
| Other study ID | “MMED008” |

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.3-5"></a>

###### Rationale for the dose levels and the placebo control

> “The 4 individual dose levels of MM-120 in the current study have been selected to assess both: 1) the dose-response relationship over a wide dose range that has been previously shown to be safe in clinical trials; and 2) the functional mechanism of action, specifically the extent to which psychedelic effects mediate clinical outcomes.”
> “Placebo control – an inactive placebo is the most appropriate control for the Multiple Comparison Procedure-Modelling (MCP-Mod) statistical approach to be used in the current study and for characterization of dose-response”
> “Threshold dose – minimum dose at which psychoactive effects are perceivable by patients on average”
> “The Sponsor concluded that no further dose increase beyond 200 μg (freebase-equivalent) would be required for predicted changes on HAM-A.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

> “The MM120 dose levels in this study (freebase-equivalent dose of 0, 25, 50, 100, or 200 μg) have been explored in previous studies and found to bracket levels of acute drug effects with 25 μg at the threshold of perception, 50 μg producing reliable acute effects, 100 μg representing a ceiling for”
> “and 200 μg sometimes leading to increased levels of effects perceived as less pleasant.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.3-6"></a>

###### Blinded central rating of efficacy outcomes

> “The HAM-A and the Montgomery-Åsberg Depression Rating Scale (MADRS) scores were assessed by independent central raters via telephone; the raters were blinded to the trial protocol, treatment allocation, and study visit.”
> “To mitigate bias, the dosing session monitors were prohibited from conducting the efficacy assessments.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.3-7"></a>

###### Single administration with no psychotherapeutic intervention

> “Study MMED008 is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study.”
> “MM-120 was administered as a single-dose in a monitored clinical setting with no additional therapeutic intervention.”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

> “Five-arm dose optimization design with 1:1:1:1:1 randomization”
> “No changes planned to drug delivery between Phase 2 and Phase 3”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Key eligibility criteria reported in the publication

> “The eligibility criteria included age of 18 to 74 years, having a Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) primary diagnosis of GAD based on investigator assessment and confirmed by a Mini-International Neuropsychiatric Interview, and having moderate to severe anxiety (Hamilton Anxiety Rating Scale [HAM-A] score of ≥20) at both screening and at baseline.”
> “The exclusion criteria included contraindicated medical or psychiatric conditions and inability or unwillingness to discontinue therapeutics with potential drug-drug interaction or anxiolytic effects.”
> “Disclosure or detection of the use of prohibited substances, including tetrahydrocannabinol, was cause for screening failure or discontinuation as was the use of any psychedelic within the past 2 years or more than 10 times within the past 10 years.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.4-2"></a>

###### Inclusion criteria in the protocol

| Criterion | Quoted protocol text |
| --- | --- |
| Age | “Age ≥ 18 to < 75 years at Screening (Visit 1)” |
| Body weight | “Body weight of ≥ 50 kg” |
| Body mass index | “Body mass index [BMI] ≥ 18 to ≤ 38 mg/kg2” |
| Diagnosis | “Diagnosis of DSM-5 generalized anxiety disorder based upon clinical assessment and confirmed by the Mini-International Neuropsychiatric Interview (MINI)” |
| Anxiety severity | “HAM-A Total Score ≥ 20 at Screening (Visit 1) and Baseline (Visit 2)” |
| Medical condition | “Acceptable overall medical condition to be safely enrolled into and to complete the study, at the discretion of the Investigator” |
| Formulation | “Ability to swallow capsules” |

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.4-3"></a>

###### Key exclusion criteria in the protocol: psychiatric history and substance use

> “Prior history (lifetime diagnosis) or known first-degree relative (i.e., mother/father/full siblings) with a lifetime diagnosis of schizophrenia spectrum, or other psychotic disorder or bipolar disorder (bipolar I, bipolar II or cyclothymic disorder)”
> “Lifetime diagnosis of Posttraumatic Stress Disorder”
> “Other current psychiatric disorders that, in the opinion of the Investigator, may confound the results of the study (e.g., major depressive disorder, obsessive-compulsive disorder,”
> “History of alcohol or substance use disorder within 12 months prior to Screening (Visit 1) (includes diagnosis of alcohol or drug use disorder per the MINI)”
> “Unwillingness or inability to discontinue prohibited concomitant medications, supplements or other therapeutics (prescription or over-the-counter)”
> “Treatment with deep brain stimulation (DBS), vagus nerve stimulation (VNS), electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within 3 months prior to Screening (Visit 1) or a plan to receive treatment with any of these from the time of providing informed consent until End of Study”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.4-4"></a>

###### Key exclusion criteria in the protocol: cardiovascular conditions

> “Uncontrolled hypertension”
> “Blood pressure (BP) outside the range of 90-140 mmHg systolic BP or 50-90 mmHg diastolic BP after an approximately 5 minutes of rest”
> “Heart rate <45 beats/minute or >90 beats/minute after an approximately 5-minute supine rest at Screening and Baseline”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.4-5"></a>

###### Suicide risk exclusion in the registry

> “Has a significant risk of suicide attempt based upon medical history or has active suicidal ideation”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.4-6"></a>

###### Concurrent psychotherapy

> “Participants undergoing psychotherapy at the time of screening could enroll but could not discontinue or modify session frequency during the study. Participants not receiving psychotherapy at screening could not initiate it during the trial.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Treatment arms in the registry

| Arm | Registry record |
| --- | --- |
| Placebo | “Placebo Comparator: Arm 1- Placebo” |
| Lysergide 25 µg | “Experimental: Arm 2- 25 μg MM120” |
| Lysergide 50 µg | “Experimental: Arm 3- 50 μg MM120” |
| Lysergide 100 µg | “Experimental: Arm 4- 100 μg MM120” |
| Lysergide 200 µg | “Experimental: Arm 5- 200 μg MM120” |
| Intervention description | “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).” |

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.5-2"></a>

###### Number randomized to each arm

> “Participants were randomized to receive a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.5-3"></a>

###### Capsule formulation and blinded dose preparation

> “MM120 drug product is a solid oral capsule that was produced by granulating LSD with inactive excipients and filling approximately 80 mg of granulation powder into a hypromellose capsule. It was manufactured by Quotient Sciences. Each MM120 capsule was formulated to contain 36.6 μg of LSD (equivalent to 25 μg lysergide freebase), and each capsule batch met the uniformity of dosage-unit requirements set forth in United States Pharmacopeia (USP)”
> “Each dose was prepared by placing 8 total capsules in a closed, desiccated, high-density polyethylene bottle. A combination of MM120 and matching placebo capsules was placed in each bottle to achieve the specified MM120 freebase-equivalent dose of 0, 25, 50, 100, or 200 μg.”
> “Each participant received 8 capsules, which were swallowed with water.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.5-4"></a>

###### Formulation relative to the phase 3 trials

> “The dose-response results support the selection of MM120 100 µg for the Company’s ongoing Phase 3 development program for MM120 Orally Disintegrating Tablet (ODT).”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.5-5"></a>

###### Medication taper and washout before dosing

> “Participants taking mood or anxiety medications at screening were required to discontinue them under the supervision of site physicians. Before the baseline visit, a medication washout period of 5 half-lives or greater was required.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Prior to treatment with MM120, study participants were clinically tapered and then washed out from any anxiolytic or antidepressant treatments and did not receive any form of study-related psychotherapy for the duration of their participation in the study.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="topic-3.1.3.5-6"></a>

###### Prohibited medications during the study

> “Categories of pharmacotherapies not permitted during the study were antipsychotics, antidepressants, barbiturates, benzodiazepines (except if indicated during the dosing session to manage AEs), cannabis, lithium, psychostimulants, and other substances known to affect serotonergic function (eg, efavirenz, kava, ginkgo biloba, St. John’s wort, and 5-hydroxytryptophan). Participants who took prohibited medication during the trial were discontinued.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.5-7"></a>

###### Dosing session procedures and monitoring

> “On the dosing day, participants received a single oral dose of MM120 or placebo. Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.”
> “Participant dosing sessions were conducted individually in a private aesthetically pleasant room. The dosing sessions were not recorded or conducted in a group setting. Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.”
> “Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.”
> “Engaging in psychotherapy with the participant was explicitly prohibited by the trial protocol (Supplement 1). Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects. Continuous monitoring was required for a minimum of 12 hours.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.5-8"></a>

###### Dosing session monitor qualifications

> “The lead DSM was a licensed healthcare provider with graduate-level professional training and clinical experience.”
> “The secondary monitor had to have a bachelor's degree and a year of clinical experience.”
> “We approved 91 lead DSMs and 41 secondary DSMs.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.5-9"></a>

###### Release from the dosing session

> “Study subjects will be kept under continuous observation for a minimum of 12 hours following investigational drug administration. Beginning approximately 8 hours after drug administration, the Dosing Release Checklist will be performed by the site-designated licensed physician (MD/DO) to evaluate the subject’s psychological and physiological status. This will include an evaluation to ascertain that the subject no longer meets DSM-5 criteria for Hallucinogen Intoxication.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Hamilton Anxiety Rating Scale Dose-Response at Week 4 as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint definition

> “The primary outcome was a dose-response relationship assessed using the multiple comparison procedure modeling (MCP-Mod) method for change in HAM-A score at 4 weeks (score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe).”
> “The HAM-A score was assessed by independent central raters using the Structured Interview Guide for the Hamilton Anxiety Rating Scale.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.6.1-2"></a>

###### Registered primary outcome and HAM-A items

> “To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 4.”
> “The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general).”
> “Minimum score = 0, maximum score = 56.”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.6.1-3"></a>

###### Protocol rationale for the HAM-A as the efficacy measure

> “The primary outcome measure for this study is the Hamilton Anxiety Rating Scale (HAM-A); a validated anxiety rating scale that has been used extensively in clinical trials (including numerous FDA registration trials) to assess anxiety symptoms across a range of psychiatric diagnoses”
> “The change in HAM-A score from baseline to post-treatment was used as the primary efficacy endpoint supporting approval of venlafaxine, paroxetine, escitalopram and duloxetine.”
> “Based on the myriad of patient populations that are sensitive to the HAM-A, the long history of use in new drug application enabling clinical trials and established validity, the HAM-A scale is fit-for-purpose to assess anxiety symptoms in subjects with GAD.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.6.1-4"></a>

###### Protocol rationale for the Week 4 time point, the Week 8 key secondary endpoint, and the HAM-A entry threshold

> “The primary endpoint for the current study is change in HAM-A Total Score from Baseline to Week 4. Preliminary evidence suggests that LSD (along with other psychedelic therapies such as psilocybin) are rapid-acting, and that acute responses to treatment are predictive of intermediate and longer-term outcomes”
> “To assess the durability of effect, the key secondary endpoint of change in HAM-A Total Score from Baseline to Week 8 will be used.”
> “Eligibility for this study is based in part on a minimum HAM-A Total Score of 20. This is to target enrollment to a population of subjects who have significant anxiety that is sensitive to measurement by the HAM-A.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.6.1-5"></a>

###### Rationale for the MCP-Mod analysis and the minimal clinically important difference

> “The primary outcome and the key secondary outcome were evaluated using the MCP-Mod approach at the 5% significance level, which integrates hypothesis testing with dose-response modeling and is endorsed by regulatory agencies for dose selection.”
> “A placebo-adjusted difference of 2.5 points for change in HAM-A score was used as the threshold (minimal clinically important difference of 2.5 points) for determining the minimally efficacious dose.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.6.1-6"></a>

###### Key secondary, secondary, and exploratory endpoints

> “The key secondary outcome was a dose-response relationship”
> “assessed using the MCP-Mod method for change in HAM-A score at 8 weeks.”
> “The rates of response (≥50% change [reduction] in HAM-A score from baseline) and remission (HAM-A score ≤7) were also explored.”
> “The effects of MM120 on functional disability, quality of life, and sexual function were assessed throughout the trial using the Sheehan Disability Scale, the EuroQol 5-dimension 5-level questionnaire, the Pittsburgh Sleep Quality Index, and the Arizona Sexual Experiences Questionnaire.”
> “Blinding of the participants and raters regarding treatment allocation (active drug, placebo, or indiscernible) was assessed using a 5-point questionnaire (range, 1 [positive they received drug] to 5 [positive they received placebo]).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.6.1-7"></a>

###### Safety endpoints

> “Safety and tolerability were evaluated through adverse event (AE) monitoring, physical and neuropsychiatric examinations, vital signs, electrocardiographic monitoring, and laboratory tests. Suicidal ideation and behavior were assessed at each visit using the Columbia–Suicide Severity Rating Scale (C-SSRS).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned sample size and power

> “To achieve a mean power greater than 87% for the MCP-Mod approach analysis, 200 participants were planned to yield at least 180 evaluable end points after any dropouts.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.7.1-2"></a>

###### Target sample size in protocol version 6.0, July 2023

> “The target sample size for this study is approximately 180 subjects.”

Source: [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)

<a id="topic-3.1.3.7.1-3"></a>

###### Planned enrollment in the registry description

> “The study will enroll approximately 200 male and female subjects 18 years to < 75 years of age who meet DSM-5 criteria for GAD and have a minimum HAM-A Total Score of 20.”

Source: [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)

<a id="topic-3.1.3.7.1-4"></a>

###### Planned enrollment at first participant dosing, August 2022

> “The trial plans to enroll 200 participants who will receive a single administration of up to 200 µg of MM-120 or placebo.”

Source: [MindMed Phase 2b first patient dosed announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/29/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.7.1-5"></a>

###### Participants randomized and analyzed

> “There were 198 participants in the Randomized Set and 198 participants in the Safety Set. Of these, 194 (98.0%) of participants were included in the Full Analysis Set and 183 (92.4%) were included in the Per Protocol Set.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

> “Of the 198 participants randomized, 194 were included in the full analysis set”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Analysis sets used for efficacy and safety

> “Efficacy was analyzed in the full analysis set, which was composed of all randomized participants with a HAM-A measurement at baseline and at least 1 HAM-A measurement after baseline. Safety was evaluated in all participants who were randomized.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.7.2-2"></a>

###### Analysis sets defined in the statistical analysis plan

> “Randomized Set (RAN) – all subjects who received a randomization number, regardless of receiving study drug.”
> “Safety Set (SAF) – all subjects who received the double-blind study drug. Subjects will be analyzed according to the actual treatment received.”
> “Full Analysis Set (FAS) – all randomized subjects with a valid baseline HAM-A assessment and at least one valid post-baseline HAM-A assessment.”
> “Per Protocol Set (PPS) - All subjects in the full analysis set who had no major protocol deviations deemed as impacting the primary endpoint.”

Source: [MindMed MMED008 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/SAP_001.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### MCP-Mod testing procedure and dose-response models

> “Six candidate dose-response models were prespecified to represent a range of plausible dose-response shapes”
> “assessed under strict type I error control at the 5% level using a hierarchical gatekeeping testing procedure.”
> “The estimated dose-response curve was derived using an Akaike information criterion–weighted average of the top 3 dose-response models.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.7.2-4"></a>

###### Handling of missing data and intercurrent events

> “Missing primary end point data were imputed using multiple imputations with 20 iterations. Observations missing due to prohibited medication use were assumed to be missing not at random and imputed using placebo-based imputation. All other missing observations were imputed under the assumption of missing at random.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.7.2-5"></a>

###### Secondary analyses without imputation or multiplicity adjustment

> “Change in HAM-A score from baseline was analyzed using an analysis of covariance model adjusted for the baseline values and treatment group without imputation (observed cases only).”
> “Other secondary efficacy outcomes were analyzed using 2-sample t tests.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Missing data was not imputed for analysis of non-key secondary efficacy endpoints or safety endpoints. No adjustment for multiplicity was performed for testing the non-key secondary and exploratory endpoints.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.7.2-6"></a>

###### Effect size calculation

> “Cohen d was calculated as the bias-corrected least-squares estimate of the treatment difference in changes from baseline to a given time point (from an analysis of covariance model), divided by the pooled SD of observed values at the same time point from a given active dose group and the placebo group.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Screening, randomization, and study completion

> “A total of 554 potential participants were screened and 356 were excluded. Of the 198 participants randomized to study treatment, 147 (74.2%) completed the study.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

###### Completion by arm in the registry

| Arm | Started | Completed | Not completed |
| --- | --- | --- | --- |
| Placebo | “39” | “26” | “13” |
| Lysergide 25 µg | “39” | “29” | “10” |
| Lysergide 50 µg | “40” | “29” | “11” |
| Lysergide 100 µg | “40” | “33” | “7” |
| Lysergide 200 µg | “40” | “30” | “10” |

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.1-3"></a>

###### Enrollment period and randomization in the publication

> “Between August 24, 2022, and August 30, 2023, a total of 554 participants were screened; of these, 198 were randomized and received a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39) (Figure 1).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.1-4"></a>

###### Withdrawals due to adverse events

> “Five participants (2.5%) withdrew due to AEs (2 participants each in the 25-µg and 50-µg dose groups and 1 participant in the 100-µg group).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.1-5"></a>

###### Sponsor summary of completion rates

> “74% 12-week completion rate of all randomized participants which is consistent with other studies in drug class”
> “79% 12-week completion rate in high dose groups”
> “Included in FAS population: 90%”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.3.8.1-6"></a>

###### Completion through Week 4 in the topline announcement

> “The overall four-week completion rate in the trial was approximately 90% and was 97.5% in the high dose groups, and no participants in the high dose groups discontinued due to an adverse event through Week 4.”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographics of the full analysis set

> “Of the 198 participants randomized, 194 were included in the full analysis set (mean age, 41.3 [SD, 13.6] years; 56.7% were female; and 3.6% were Asian, 7.7% were Black or African American, and 83.0% were White) (Table 1).”
> “The mean HAM-A scores at baseline were equivalent across groups (score range, 29.3-31.0).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.2-2"></a>

###### Baseline demographics and disease characteristics by arm

| Characteristic | Placebo (n = 39) | 25 µg (n = 39) | 50 µg (n = 36) | 100 µg (n = 40) | 200 µg (n = 40) |
| --- | --- | --- | --- | --- | --- |
| Age, median (IQR), y | “37 (28.5-47.5)” | “35 (30.5-43.0)” | “47 (33.0-57.3)” | “41 (29.0-55.5)” | “38.5 (33.8-55.0)” |
| Female, No. (%) | “26 (66.7)” | “20 (51.3)” | “20 (55.6)” | “16 (40.0)” | “28 (70.0)” |
| White, No. (%) | “30 (76.9)” | “33 (84.6)” | “29 (80.6)” | “36 (90.0)” | “33 (82.5)” |
| Black or African American, No. (%) | “6 (15.4)” | “3 (7.7)” | “2 (5.6)” | “1 (2.5)” | “3 (7.5)” |
| Hispanic or Latino, No. (%) | “8 (20.5)” | “5 (12.8)” | “6 (16.7)” | “6 (15.0)” | “6 (15.0)” |
| Time from GAD diagnosis, median (IQR), y | “11.0 (4.5-18.8)” | “7.0 (3.2-14.0)” | “12.9 (6.0-17.4)” | “11.2 (3.1-20.3)” | “11 (5.8-20.7)” |
| HAM-A score, mean (SD) | “30.3 (6.6)” | “30.2 (6.1)” | “30.3 (5.7)” | “29.3 (6.4)” | “31.0 (7.0)” |
| CGI-S score, mean (SD) | “4.9 (0.6)” | “4.9 (0.8)” | “4.9 (0.6)” | “4.8 (0.8)” | “5.1 (0.7)” |
| MADRS score, mean (SD) | “27.6 (9.7)” | “25.4 (7.6)” | “27.7 (8.3)” | “26.5 (8.0)” | “28.9 (8.3)” |
| Continued psychotherapy during trial, No. (%) | “9 (23.1)” | “3 (7.7)” | “11 (27.5)” | “5 (12.5)” | “7 (17.5)” |
| Comorbid major depression, No. (%) | “17 (43.6)” | “12 (30.8)” | “17 (47.2)” | “18 (45.0)” | “15 (37.5)” |
| Comorbid social anxiety disorder, No. (%) | “9 (23.1)” | “6 (15.4)” | “5 (13.9)” | “4 (10.0)” | “5 (12.5)” |
| Comorbid panic disorder, No. (%) | “7 (17.9)” | “5 (12.8)” | “4 (11.1)” | “2 (5.0)” | “5 (12.5)” |
| SSRI or SNRI taper at enrollment, No. (%) | “25 (64.1)” | “25 (64.1)” | “28 (77.8)” | “21 (52.5)” | “16 (40.0)” |
| Benzodiazepine taper at enrollment, No. (%) | “9 (23.1)” | “6 (15.4)” | “9 (25.0)” | “2 (5.0)” | “14 (35.0)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.2-3"></a>

###### Prior treatment and medication taper at screening

> “At screening, 84% of participants required tapering prohibited medications, 16% were treatment-naive, and 18% were receiving psychotherapy at the time of enrollment; psychotherapy was allowed to continue through the trial. Of the participants who required tapering prohibited medications, 43% were taking serotonin reuptake inhibitors, 34% were taking benzodiazepines, and 19% were taking antipsychotics or antiepileptics.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.2-4"></a>

###### Baseline severity described by the sponsor

> “Subjects enrolled in the trial presented with severe GAD symptoms (average baseline HAM-A scores of approximately 30).”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary endpoint: MCP-Mod dose-response for HAM-A change at Week 4

> “A significant MM120 dose-response relationship was demonstrated at both week 4 (primary outcome) and week 8 (key secondary outcome) based on changes from baseline in HAM-A score.”
> “At week 4, the adjusted critical value was 2.032 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 3.294, 3.149, 3.133, 1.448, 3.471, and 2.971, respectively. Therefore, 5 of the 6 models, including the linear, Emax, and multiple sigmoid Emax variants, met the significance threshold.”
> “For the primary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 4 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −5.0 points [95% CI, −9.6 to −0.4 points] with 100 µg of MM120 and −6.0 points [95% CI, −9.8 to −2.0 points] with 200 µg of MM120) but the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −1.2 points [95% CI, −6.0 to 3.5 points] with 25 µg of MM120 and −1.8 points [95% CI, −7.6 to 4.0 points] with 50 µg of MM120)”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-2"></a>

###### Primary endpoint: model-based estimates at Week 4 by arm

| Arm | Least-squares mean change (95% CI) | Least-squares mean difference vs placebo (95% CI) |
| --- | --- | --- |
| Placebo | “−14.2 (−17.8 to −10.6)” | Not applicable |
| Lysergide 25 µg | “−15.4 (−17.6 to −13.1)” | “−1.2 (−6.0 to 3.5)” |
| Lysergide 50 µg | “−16.0 (−19.4 to −12.7)” | “−1.8 (−7.6 to 4.0)” |
| Lysergide 100 µg | “−19.2 (−21.7 to −16.7)” | “−5.0 (−9.6 to −0.4)” |
| Lysergide 200 µg | “−20.1 (−22.9 to −17.3)” | “−6.0 (−9.8 to −2.0)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-3"></a>

###### Primary endpoint as posted on the registry

| Arm | Mean change from baseline to Week 4, model averaging (95% CI) | Mean difference from placebo (95% CI) |
| --- | --- | --- |
| Placebo | “-14.23 (-17.83 to -10.63)” | Not applicable |
| Lysergide 25 µg | “-15.35 (-17.62 to -13.09)” | “-1.24 (-6.01 to 3.53)” |
| Lysergide 50 µg | “-16.05 (-19.40 to -12.71)” | “-1.82 (-7.65 to 4.00)” |
| Lysergide 100 µg | “-19.22 (-21.73 to -16.70)” | “-5.02 (-9.60 to -0.44)” |
| Lysergide 200 µg | “-20.09 (-22.87 to -17.31)” | “-5.95 (-9.84 to -2.06)” |

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.3-4"></a>

###### Minimally efficacious dose

> “These selected models at each time point were incorporated into an Akaike information criterion–weighted model-averaging procedure to estimate the dose-response curve and calculate the minimally efficacious dose, which was found to be between 56.7 µg and 85.1 µg (eFigure 2 in Supplement 3).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-5"></a>

###### Key secondary endpoint: MCP-Mod dose-response for HAM-A change at Week 8

> “At week 8, the adjusted critical value was 2.041 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 2.099, 2.922, 2.938, 2.254, 2.690, and 2.778, respectively. Therefore, all 6 models met the significance threshold, with the linear, Emax, and sigmoid Emax models selected as the best fitting.”
> “For the key secondary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 8 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −2.9 points [95% CI, −5.4 to −0.5 points] with 100 µg of MM120 and −5.4 points [95% CI, −9.5 to −1.4 points] with 200 µg of MM120) but”
> “the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −0.8 points [95% CI, −1.7 to 0.2 points] with 25 µg of MM120 and −1.4 points [95% CI, −3.1 to 0.2 points] with 50 µg of MM120)”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-6"></a>

###### Week 4 HAM-A difference at 100 µg: observed-case ANCOVA secondary analysis in the publication

> “For the secondary outcome at week 4, the 100-µg and the 200-µg dose groups significantly reduced HAM-A score vs placebo (the least-squares mean difference was −7.6 points [95% CI, −11.8 to −3.4 points; P < .001; Cohen d = 0.88] with 100 µg of MM120 and was −5.5 points [95% CI, −9.7 to −1.3 points; P = .01; Cohen d = 0.64] with 200 µg of MM120)”
> “At week 4, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −3.4 points (95% CI, −7.7 to 0.9 points; P = .12) with 25 µg of MM120 and the reduction was −0.9 points (95% CI, −5.2 to 3.3 points; P = .66) with 50 µg of MM120.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-7"></a>

###### Week 4 HAM-A difference at 100 µg: company topline announcement, December 2023

> “MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo at Week 4 (p=0.0004, Cohen’s d effect size = 0.88)”
> “MM-120 100 µg – the dose achieving the highest level of clinical activity – demonstrated a 7.6-point reduction compared to placebo at Week 4 (-21.3 MM-120 vs. -13.7 placebo; p<0.0004; Cohen’s d=0.88).”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.8.3-8"></a>

###### Week 4 HAM-A difference at 100 µg: company publication announcement, September 2025

> “At Week 4, it achieved a 7.6-point greater reduction in HAM-A scores compared to placebo (-21.3 vs. -13.7; p<0.0004; Cohen’s d=0.88) with a 65% clinical response rate and 48% clinical remission rate sustained to Week 12.”
> “MM120 100 and 200 µg significantly reduced HAM-A from baseline to Week 4 with placebo-adjusted improvement in HAM-A of -7.6 (95% CI, -11.8 to -3.4; p<0.001, and -5.50 (95% CI, -9.7 to -1.3; p=0.01) points, while 25 and 50 µg did not reach statistical significance, demonstrating placebo-adjusted improvements of -3.4 (95% CI, -7.7 to 0.9; p=0.12) and -0.9 (95% CI, -5.2 to 3.3; p=0.66).”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.8.3-9"></a>

###### HAM-A change from baseline by week: observed-case ANCOVA differences from placebo

| Week | 25 µg | 50 µg | 100 µg | 200 µg |
| --- | --- | --- | --- | --- |
| Week 1 | “−4.3 (−8.5 to −0.1)” | “−2.5 (−6.7 to 1.7)” | “−8.1 (−12.3 to −3.9)” | “−6.0 (−10.2 to −1.8)” |
| Week 2 | “−3.4 (−7.5 to 0.8)” | “−1.5 (−5.7 to 2.8)” | “−7.1 (−11.3 to −2.9)” | “−7.5 (−11.6 to −3.3)” |
| Week 4 | “−3.4 (−7.7 to 0.9)” | “−0.9 (−5.2 to 3.3)” | “−7.6 (−11.8 to −3.4)” | “−5.5 (−9.7 to −1.3)” |
| Week 8 | “−2.9 (−7.6 to 1.8)” | “0.85 (−3.9 to 5.6)” | “−4.3 (−8.9 to 0.3)” | “−5.5 (−10.2 to −0.8)” |
| Week 12 | “−4.3 (−9.3 to 0.8)” | “−3.2 (−8.2 to 1.9)” | “−7.7 (−12.6 to −2.8)” | “−7.4 (−12.4 to −2.4)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-10"></a>

###### HAM-A change at Weeks 8 and 12

> “For the secondary outcome at week 8, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −4.3 points (95% CI, −8.9 to 0.3 points; P = .06; Cohen d = 0.48) for 100 µg of MM120 and the reduction was −5.5 points (95% CI, −10.2 to −0.8 points; P = .02; Cohen d = 0.60) for 200 µg of MM120. At week 12, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −7.7 points (95% CI, −12.6 to −2.8 points; P = .003; Cohen d = 0.81) with 100 µg of MM120 and the reduction was −7.4 points (95% CI, −12.4 to −2.4 points; P = .004; Cohen d = 0.77) with 200 µg of MM120.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-11"></a>

###### HAM-A change at Week 12: company topline announcement, March 2024

> “MM120 100 µg – the dose with optimal clinical activity observed in the trial – demonstrated a 7.7-point improvement over placebo at Week 12 (-21.9 MM120 vs. -14.2 placebo; p<0.003 Cohen’s d=0.81), with a 65% clinical response rate and a 48% clinical remission rate sustained to Week 12.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="topic-3.1.3.8.3-12"></a>

###### HAM-A response and remission at Week 12

> “The secondary outcome of HAM-A response (defined by a 50% reduction in total score) at week 12 was achieved by 65.0% of participants in the 100-µg dose group and by 62.5% in the 200-µg dose group compared with 30.8% of participants in the placebo group and the remission rates at week 12 were 47.5%, 45.0%, and 20.5%, respectively (eFigure 4 and eTable 3 in Supplement 3).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-13"></a>

###### HAM-A response and remission at Weeks 4 and 12 by arm

| Outcome | Placebo (n=39) | 25 μg (n=39) | 50 μg (n=36) | 100 μg (n=40) | 200 μg (n=40) |
| --- | --- | --- | --- | --- | --- |
| Response, Week 4, n (%) | “12 (30.8%)” | “20 (51.3%)” | “21 (58.3%)” | “31 (77.5%)” | “31 (77.5%)” |
| Response, Week 12, n (%) | “12 (30.8%)” | “17 (43.6%)” | “20 (55.6%)” | “26 (65.0%)” | “25 (62.5%)” |
| Remission, Week 4, n (%) | “7 (17.9%)” | “11 (28.2%)” | “9 (25.0%)” | “20 (50.0%)” | “14 (35.0%)” |
| Remission, Week 12, n (%) | “8 (20.5%)” | “11 (28.2%)” | “12 (33.3%)” | “19 (47.5%)” | “18 (45.0%)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

> “HAM-A response was defined as ≥50% reduction in the HAM-A. HAM-A remission was defined as a HAM-A ≤7”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.3-14"></a>

###### HAM-A response and remission at Week 4: company topline announcement, December 2023

> “Clinical response (50% or greater improvement in HAM-A) at Week 4 was achieved in 78% of participants treated with MM-120 (100 µg or 200 µg) compared to 31% for placebo. Clinical remission (HAM-A ≤ 7) at Week 4 was achieved in 50% of participants treated with MM-120 100 µg.”

Source: [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)

<a id="topic-3.1.3.8.3-15"></a>

###### Clinician-rated illness severity (CGI-S)

> “The statistically significant improvements in illness severity (measured using the CGI-S score) were observed on day 2 and at weeks 2 through 12 in the 100-µg and 200-µg dose groups, but not in the 25-µg or 50-µg dose groups or in the placebo group. At week 1, all MM120 dose groups demonstrated significant improvements, but the placebo group did not”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-16"></a>

###### CGI-S mean difference from placebo on Day 2 and at Week 12

| Time point | 25 µg | 50 µg | 100 µg | 200 µg |
| --- | --- | --- | --- | --- |
| Day 2 | “−0.3 (−0.8 to 0.2)” | “−0.4 (−0.9 to 0.1)” | “−1.1 (−1.7 to −0.6)” | “−0.8 (−1.4 to −0.2)” |
| Week 12 | “−0.4 (−1.2 to 0.4)” | “−0.6 (−1.5 to 0.2)” | “−1.2 (−2.0 to −0.4)” | “−1.1 (−1.9 to −0.2)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-17"></a>

###### CGI-S change described by the sponsor

> “CGI-S scores on average improved from 4.8 to 2.2 in the 100 µg dose group, representing a two-category shift from ‘markedly ill’ to ‘borderline ill’ at Week 12, compared with 4.9 to 3.5 in the placebo group (p=0.003).”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

> “1.8-point reduction in CGI-S within 24 hours (p<0.0001)”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.3.8.3-18"></a>

###### Depressive symptoms (MADRS)

> “Significant improvement in depressive symptoms (as measured by MADRS score) was observed from weeks 1 through 12 in the 100-µg and 200-µg dose groups, but not in the 25-µg and 50-µg dose groups”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-19"></a>

###### MADRS mean difference from placebo at Weeks 4 and 12

| Week | 25 µg | 50 µg | 100 µg | 200 µg |
| --- | --- | --- | --- | --- |
| Week 4 | “1.0 (−4.4 to 6.4)” | “0.1 (−5.1 to 5.3)” | “−5.7 (−11.0 to −0.5)” | “−5.9 (−11.1 to −0.7)” |
| Week 12 | “−1.6 (−7.3 to 4.0)” | “−2.3 (−7.3 to 2.6)” | “−6.4 (−11.9 to −0.9)” | “−7.6 (−13.1 to −2.1)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-20"></a>

###### MADRS change described by the sponsor

> “MADRS score improvements in the 100 µg arm of the study were clinically and statistically significant compared to the placebo group, with a difference of 5.7 points (p≤0.05) at week 4 and a difference of 6.4 points (p≤0.05) at week 12.”

Source: [MindMed APA presentation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/144/mindmed-presents-phase-2b-study-of-mm120-for-generalized-anxiety-disorder-gad-at-american-psychiatric-association-apa-annual-meeting-in-new-york)

<a id="topic-3.1.3.8.3-21"></a>

###### Functional unblinding and placebo response

> “All doses of MM120 produced transient perceptual, cognitive, and emotional effects leading to participant unblinding.”
> “despite approximately 85% of participants correctly identifying assignment to active treatment.”
> “In addition, even though more than 65% of participants accurately identified their assignment as placebo recipients, a robust placebo effect was observed that was comparable with or exceeded trials of anxiolytics.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.3-22"></a>

###### Subgroup analyses

> “The analyses of the treatment response by sex and other participant characteristics were not conducted due to insufficient statistical power to evaluate meaningful differences within dosing groups.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Functional, quality-of-life, sleep, and sexual function outcomes reported in the supplement

> “Additional secondary outcomes, including changes in scores for the Sheehan Disability Scale, the EuroQol 5-dimension 5-level questionnaire, the Pittsburgh Sleep Quality Index, and the Arizona Sexual Experiences Questionnaire appear in eTable 6 in Supplement 3.”
> “For the secondary outcomes focused on functional disability, the changes from baseline were analyzed descriptively.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.4-2"></a>

###### Sheehan Disability Scale total score at Week 12

| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
| --- | --- | --- | --- |
| Placebo | “-8.2 (8.61)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-10.8 (7.72)” | “-2.59” | “(-7.10 to 1.91)” |
| Lysergide 50 μg | “-9.0 (9.17)” | “-0.83” | “(-5.70 to 4.03)” |
| Lysergide 100 μg | “-15.1 (5.78)” | “-6.86” | “(-10.89 to -2.83)” |
| Lysergide 200 μg | “-13.1 (7.51)” | “-4.93” | “(-9.33 to -0.53)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.4-3"></a>

###### EQ-5D-5L visual analog scale at Week 12

| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
| --- | --- | --- | --- |
| Placebo | “11.7 (18.24)” | Not applicable | Not applicable |
| Lysergide 25 μg | “17.0 (18.53)” | “5.31” | “(-4.65 to 15.27)” |
| Lysergide 50 μg | “13.2 (13.97)” | “1.55” | “(-7.34 to 10.45)” |
| Lysergide 100 μg | “17.7 (13.68)” | “6.04” | “(-2.61 to 14.70)” |
| Lysergide 200 μg | “17.3 (19.40)” | “5.64” | “(-4.37 to 15.65)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.4-4"></a>

###### Pittsburgh Sleep Quality Index global score at Week 12

| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
| --- | --- | --- | --- |
| Placebo | “-4.3 (4.22)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-5.5 (4.01)” | “-1.25” | “(-3.48 to 0.99)” |
| Lysergide 50 μg | “-4.8 (3.88)” | “-0.55” | “(-2.77 to 1.67)” |
| Lysergide 100 μg | “-5.9 (4.13)” | “-1.64” | “(-3.84 to 0.56)” |
| Lysergide 200 μg | “-4.9 (4.11)” | “-0.60” | “(-2.83 to 1.62)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.4-5"></a>

###### Patient Global Impression of Severity and of Change at Week 12

| Arm | PGI-S difference from placebo in mean change | PGI-S 95% CI | PGI-C observed mean (SD) | PGI-C difference from placebo | PGI-C 95% CI |
| --- | --- | --- | --- | --- | --- |
| Placebo | Not applicable | Not applicable | “2.2 (0.98)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-0.34” | “(-0.91 to 0.24)” | “1.8 (0.71)” | “-0.36” | “(-0.83 to 0.10)” |
| Lysergide 50 μg | “-0.30” | “(-0.94 to 0.34)” | “1.8 (1.00)” | “-0.36” | “(-0.90 to 0.17)” |
| Lysergide 100 μg | “-0.47” | “(-1.05 to 0.11)” | “1.5 (0.67)” | “-0.71” | “(-1.16 to -0.25)” |
| Lysergide 200 μg | “-0.37” | “(-1.01 to 0.26)” | “1.7 (0.98)” | “-0.51” | “(-1.04 to 0.01)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.4-6"></a>

###### Sexual dysfunction (ASEX) at Week 12

| Arm | Females with sexual dysfunction, n (%) | Males with sexual dysfunction, n (%) |
| --- | --- | --- |
| Placebo | “6 (33.3)” | “1 (12.5)” |
| Lysergide 25 μg | “4 (25.0)” | “3 (23.1)” |
| Lysergide 50 μg | “10 (66.7)” | “1 (7.1)” |
| Lysergide 100 μg | “6 (46.2)” | “2 (10.0)” |
| Lysergide 200 μg | “7 (33.3)” | “0 (0)” |

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Overview of adverse events

> “The rate for 1 or more treatment-emergent adverse events (TEAEs) was 76.9% in the 25 µg of MM120 group, was 90.0% in the 50-µg group, was 97.5% in the 100-µg group, and was 100% in the 200-µg group vs 56.4% in the placebo group (Table 3).”
> “Of all the AEs, 98.5% occurred on the dosing day and most resolved by the end of the dosing session.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.5-2"></a>

###### Adverse events in the safety population by arm

| Event, No. (%) | Placebo (n = 39) | 25 µg (n = 39) | 50 µg (n = 40) | 100 µg (n = 40) | 200 µg (n = 40) |
| --- | --- | --- | --- | --- | --- |
| At least 1 TEAE | “22 (56.4)” | “30 (76.9)” | “36 (90.0)” | “39 (97.5)” | “40 (100)” |
| Any treatment-related TEAE | “16 (41.0)” | “29 (74.4)” | “32 (80.0)” | “38 (95.0)” | “40 (100)” |
| Moderate AE | “10 (25.6)” | “12 (30.8)” | “20 (50.0)” | “23 (57.5)” | “28 (70.0)” |
| Visual perception changes | “4 (10.3)” | “18 (46.2)” | “30 (75.0)” | “37 (92.5)” | “40 (100)” |
| Nausea | “3 (7.7)” | “3 (7.7)” | “11 (27.5)” | “16 (40.0)” | “24 (60.0)” |
| Headache | “9 (23.1)” | “5 (12.8)” | “9 (22.5)” | “14 (35.0)” | “11 (27.5)” |
| Euphoric mood | “1 (2.6)” | “2 (5.1)” | “5 (12.5)” | “11 (27.5)” | “6 (15.0)” |
| Mydriasis | “1 (2.6)” | “1 (2.6)” | “7 (17.5)” | “8 (20.0)” | “4 (10.0)” |
| Hyperhidrosis | “0” | “1 (2.6)” | “4 (10.0)” | “9 (22.5)” | “5 (12.5)” |

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.5-3"></a>

###### Most frequent dosing-day adverse events at 100 µg and 200 µg

> “On the dosing days, the most frequent AEs reported in the 100-µg and 200-µg dose groups were visual perceptual changes (illusion, pseudo-hallucination, hallucination) in 92.5% and 100% of participants, respectively, nausea in 40.0% and 60.0%, headache in 35.0% and 27.5%, and euphoric mood in 27.5% and 15.0%.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.5-4"></a>

###### Most common adverse events as stated in the company publication announcement, September 2025

> “MM120 had adverse events consistent with the expected effects of LSD including visual perceptual changes (illusion, pseudo-hallucination, and visual hallucination) occurring in 51.4%, 77.5%, 92.5%, 100%, and 10.3%; nausea in 7.7%, 27.5%, 42.5%, 65.0%, and 7.7%; and headache in 15.4%, 27.5%, 35.0%, 27.5%, and 23.1%, in the 25, 50, 100, 200 µg, and placebo groups, respectively.”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.8.5-5"></a>

###### Serious adverse events

> “One SAE occurred during the study when a participant in the 50-µg dose group was hospitalized for a panic attack that occurred 97 days after the dosing day and was deemed unrelated to the study drug.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Participant received MM120 on 26 January 2023. On Study Day 98, the participant experienced an SAE of moderate panic attack requiring hospitalization. It was considered not related to treatment and recovered same day.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.5-6"></a>

###### Suicidal ideation and behavior

> “No participants engaged in self-injurious or suicidal behavior, which was assessed using the C-SSRS and AE reporting. There were no reports of suicidal ideation with intent or a plan during the sessions or throughout the trial. Participants with a history of suicidal ideation showed no increase in severity.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “As measured by C-SSRS, active SI without intent or plan was reported at week 12 by 1 placebo participant and at week 8 by 1 MM120 25 μg participant, both of whom had a history of similar or more severe SI.”
> “The site physician was involved in each case of reported or detected SI, and all cases were effectively assessed and managed on an outpatient basis.”

Source: [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-3.1.3.8.5-7"></a>

###### Suicidal ideation reported as an adverse event in the registry

| Arm | Affected / at risk (%) |
| --- | --- |
| Placebo | “1/39 (2.56%)” |
| Lysergide 25 μg | “1/39 (2.56%)” |
| Lysergide 50 μg | “2/40 (5.00%)” |
| Lysergide 100 μg | “2/40 (5.00%)” |
| Lysergide 200 μg | “0/40 (0.00%)” |

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.5-8"></a>

###### Adverse event collection period

> “AE collection will occur from the time informed consent is given until Week 12 (or early discontinuation) and will be recorded at each visit.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

<a id="topic-3.1.3.8.5-9"></a>

###### Resolution of acute effects and time to meeting session-end criteria

> “Resolution of acute effects from MM120 was observed in more than 97% of participants at all MM120 doses by 12 hours after the dose was administered (eFigure 6 in Supplement 3). In the 100-µg dose group, 45.0% of participants met criteria to safely end the session at 8 hours, 70.0% at 9 hours, 87.5% at 10 hours, 90.0% at 11 hours, and 97.5% at 12 hours. All participants remained at the study site until 12 hours after the dosing session regardless of meeting criteria to safely end the session per the trial protocol (Supplement 1).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.8.5-10"></a>

###### Sponsor summary of tolerability

> “Virtually all AEs (99%) were mild-to-moderate in severity”
> “Minimal (2.5%) TEAEs led to study withdrawal”
> “One serious adverse event (SAE) was observed in the 50 μg dose group: panic attack on study day 98 that was deemed not related to treatment.”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.3.8.5-11"></a>

###### Pooled safety analysis including the phase 2b 100 µg and 200 µg arms

> “Multicenter, randomized, double-blind, dose-finding in participants with GAD”
> “Across all 4 studies, there were no treatment-related serious adverse events (AEs), hallucinogen persisting perception disorder, or deaths after treatment with DT120”
> “Similarly, there was no worsening of preexisting passive suicidal ideation, no active suicidal ideation or behaviors, and no evidence of session-induced suicidal ideation”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The trial randomized 198 participants at 22 outpatient sites in the United States to a single dose of lysergide capsules (25, 50, 100, or 200 µg) or placebo, with 12 weeks of follow-up and no study-related psychotherapy. The phase 3 trials use an orally disintegrating tablet, so the phase 2b results were obtained with a different formulation.

- Primary analysis and reported effect size: the prespecified MCP-Mod primary analysis with multiple imputation gave a least-squares mean difference from placebo at Week 4 of −5.0 points (95% CI, −9.6 to −0.4) for 100 µg. The 7.6-point difference (Cohen d = 0.88) that company announcements report for Week 4 is the publication's secondary outcome at Week 4. The publication states that change in HAM-A score from baseline was analyzed by analysis of covariance without imputation (observed cases only), while missing primary end point data were imputed by multiple imputation; the registry results state that missing data were not imputed for non-key secondary efficacy endpoints.
- Multiplicity: only the primary and key secondary outcomes were controlled for type I error; other hypothesis tests, including the Week 12 difference of −7.7 points and the response and remission rates, were not adjusted for multiple comparisons.
- Functional unblinding: the authors state that the perceptible drug effects may have led to unblinding, and approximately 85% of participants correctly identified assignment to active treatment. Efficacy was rated by central raters blinded to protocol, treatment allocation, and visit.
- Dosing session monitors: two monitors were present throughout each session, and the authors state that confounding effects of interpersonal interactions remain a possibility.
- Missing data: 147 of 198 randomized participants (74.2%) completed the study, and the authors describe the dropout rate as slightly higher than in studies of similar molecules.
- Population: participants were physically healthy with limited psychiatric comorbidities, discontinued anxiolytic and antidepressant medications before dosing, and 83.0% were White; 18% received psychotherapy outside the trial.
- Sample size: 36 to 40 participants per arm in the full analysis set; analyses by sex and other characteristics were not conducted because of insufficient statistical power.
- Adverse event figures for visual perceptual changes, nausea, and headache in the company publication announcement differ from those in the journal article (for example, nausea at 100 µg 42.5% versus 40.0%).

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf); [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results); [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder); [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.3.9-2"></a>

###### Limitations stated in the publication

> “Despite dosing session monitors explicitly not providing a systematic psychotherapeutic intervention, confounding effects of interpersonal interactions remain a possibility.”
> “Second, the perceptible drug effects of MM120 may have led to unblinding, which could have influenced the outcomes.”
> “Third, the primary outcome and key secondary outcome were strictly controlled for type I error, but the other hypothesis tests were not adjusted for multiple comparisons. Fourth, the dropout rate, though similar across groups, was slightly higher than in studies of similar molecules.”
> “This higher dropout rate may be due to the 12-week duration of the trial, the required discontinuation of GAD medications, and the absence of an extension phase with opportunities for open-label treatment. Fifth, the participants were physically healthy with limited psychiatric comorbidities, potentially enhancing the tolerability of transient AEs. Sixth, the process of tapering participants from prohibited psychoactive medications ensured MM120 was assessed as a monotherapy; however, we did not address concomitant use of other pharmacotherapies. Seventh, some participants engaged in psychotherapy outside the trial, which may have affected dosing-day experiences and efficacy outcomes, though this was the case for only 18% of participants. Eighth, the study population was inclusive in terms of sex and age but was racially and ethnically less diverse than the general population of people with GAD.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.3.9-3"></a>

###### Limitations and caveats in the registry results

> “DSMs assisted and monitored participants which could be construed to have an independent therapeutic effect. So, DSMs were given training to not engage in psychotherapy with participants. There was a potential for unblinding so blinded independent central raters assessed the primary efficacy outcome.”

Source: [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)

Additional sources: [Soares (2025)](https://pubmed.ncbi.nlm.nih.gov/40906492/)

<a id="heading-3.1.4"></a>

#### 3.1.4 LSD-assist

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Registered objective

> “Objective: To test the efficacy of LSD in patients with anxiety with or without life-threatening diseases.”
> “This study will evaluate the potential benefits of single treatments with LSD in anxiety disorder.”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.1-2"></a>

###### Published aim of the primary analysis

> “This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.1-3"></a>

###### Aim of the long-term follow-up

> “We investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness.”
> “We hypothesised effects would not be sustained up to the 12-month follow-up.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.1-4"></a>

###### Role in the development of DT120 (MM-120)

> “Data further validates MindMed's therapeutic approach and supports the clinical development of MM-120 for the treatment of Generalized Anxiety Disorder”
> “MindMed supports the UHB Liechti Lab in conducting investigator-initiated trials for LSD and other novel therapies and has exclusive access and rights to the data generated by these studies.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study identifiers, dates, and status

| Item | Registry record |
| --- | --- |
| Brief title with acronym | “LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders (LSD-assist)” |
| Other study ID | “BASEC 2016-00992” |
| Phase | “Phase 2” |
| Study start (actual) | “2017-06-23” |
| Primary completion (actual) | “2021-12-15” |
| Study completion (actual) | “2021-12-15” |
| First posted | “2017-05-15” |
| Last update posted | “2021-12-22” |
| Results | “No Results Posted” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.2-2"></a>

###### Sites: two centers in Switzerland

> “This study has 2 locations”
> “Basel, Canton of Basel-City, Switzerland, 4056 University Hospital Basel”
> “Solothurn, Canton of Solothurn, Switzerland, 4500 Private Practice P.Gasser”
> “Sponsor University Hospital, Basel, Switzerland”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

> “The study was an investigator-initiated, two-centre trial, with one study centre at the University Hospital Basel, Switzerland, and the other study centre at the Clinic Dr Peter Gasser, Solothurn, Switzerland.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.2-3"></a>

###### Enrollment period, last visit, and follow-up completion

> “Enrolment began on 23 June 2017 and finished on 1 February 2021. The trial ended as planned, with the last patient visit on 15 December 2021. The assessment of follow-up questionnaires was completed by January 2023.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.2-4"></a>

###### First presentation of results, May 2022

> “These findings were presented in an oral presentation at London's PSYCH Symposium on May 11, 2022.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Official title and registered design

> “LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study”
> “Design: Double-blind, placebo-controlled random-order cross-over trial using two LSD (200 µg) and two placebo sessions with subjects acting as their own control.”
> “Interventional Model Description: randomized, double-blind, placebo-controlled, crossover”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

| Design element | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.3-2"></a>

###### Two-center, two-period, random-order crossover design

> “The study is an investigator-initiated 2-center trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or placebo per period.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.3-3"></a>

###### Treatment periods, session spacing, and visit schedule

> “The order of administration was random and counterbalanced.”
> “After study inclusion, the participants were randomly assigned to LSD or placebo in the first treatment period and vice versa in the second treatment period by order of enrolment and group.”
> “As previously reported in detail, the study included a screening visit and two 24-week treatment periods per participant. Each treatment period consisted of two treatment sessions and five study visits. Treatment sessions were separated by 6 weeks (±2 weeks). Study visits were conducted at baseline, between treatment sessions, and 2, 8 and 16 weeks after the second treatment session. The last visit in the second period also served as the end-of-study visit.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

> “Patients were randomly assigned to two sessions with either oral LSD (200 µg) or placebo administration over a trial duration of 52 weeks per patient.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.3-4"></a>

###### Planned long-term follow-up by mailed questionnaire

> “Follow-up questionnaires were sent by mail to all participants (including dropouts) 12 months after the end-of-study visit.”
> “For those who received LSD in the first period, the follow-up was assessed 94 weeks after the last LSD treatment. For those who received placebo in the first period, the follow-up was assessed 68 weeks after the last LSD treatment.”
> “The follow-up was conducted 12 months after the end-of-study visit by post to investigate the same outcome measures as during the study, in which participants completed questionnaires about long-lasting effects and answered questions about adverse events.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.3-5"></a>

###### Funding, ethics approval, and licensing of the data to the developer of DT120

> “The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines in Good Clinical Practice and approved by the Ethics Committee of Northwest Switzerland (EKNZ), Swiss Federal Office for Public Health, and Swissmedic”
> “The study was funded by the University Hospital Basel and Swiss Medical Society for Psycholytic Therapy (SAePT). The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing the report. M.E.L. and P.G. are consultants for Mind Medicine, Inc.”
> “Knowhow and data associated with this work and owned by the University Hospital Basel were licensed by Mind Medicine, Inc., which had no role in financing, planning or conducting the present study or the present publication.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Age | “Age > 25 years.” |
| Anxiety diagnosis or severity | “Meet DSM-IV criteria for anxiety disorder as indicated by the Structured Clinical Interview for the DSM (SCID)-IV or have a score of at least 40 on the state- or trait STAI scale at study inclusion.” |
| Proportion with life-threatening illness | “40% or more of the participants should have a diagnosis of advanced-stage potentially fatal illness (autoimmune, neurological, or cancer without central nervous system (CNS) involvement).” |
| Life expectancy | “Patients should be ambulatory and not terminal and likely to have a roughly estimated life expectancy of > twelve months.” |
| Participants without life-threatening illness | “Patients without advanced-stage potentially fatal illness need to meet DSM-IV criteria for anxiety disorder (elevated STAI score not sufficient for inclusion)” |
| Psychiatric medication | “Participants are willing to refrain from taking any psychiatric medications during the experimental session period.” |
| Washout of antidepressants and anxiolytics | “If they are being treated with antidepressants or are taking anxiolytic medications on a fixed daily regimen such drugs must be discontinued long enough before the LSD/placebo treatment session to avoid the possibility of a drug-drug interaction (the interval will be at least 5 times the particular drug's half-life [typically 3-7 days]).” |
| Ongoing psychotherapy | “If in ongoing psychotherapy, those recruited into the study may continue to see their outside therapist, provided they sign a release for the investigators to communicate directly with their therapist.” |
| Other psychoactive drugs | “Participants must also refrain from the use of any psychoactive drugs, with the exception of the long term pain medication or caffeine or nicotine, within 24 hours of each LSD/placebo treatment session.” |
| Driving | “Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD/placebo administration.” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.4-2"></a>

###### Exclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Pregnancy and contraception | “Women who are pregnant or nursing, or of child bearing potential and are not practicing an effective means of birth control” |
| Psychotic disorder | “Past or present diagnosis of a primary psychotic disorder.” |
| Family history of psychosis | “Subjects with a first degree relative with psychotic disorders are also excluded.” |
| Bipolar disorder | “Past or present bipolar disorder (DSM-IV)” |
| Substance use disorder | “Current substance use disorder (within the last 2 months, DSM-V, except nicotine)” |
| Somatic disorders | “Somatic disorders including central nervous system (CNS) involvement of the cancer, severe cardiovascular disease, untreated hypertension, severe liver disease (liver enzymes increase by more than 5 times the upper limit or normal) or severely impaired renal function (estimated creatinine clearance <30 ml/min)” |
| Body weight | “Weight < 45 kg” |
| Suicide risk | “Suicide risk or likely to require psychiatric hospitalization during the course of the study” |
| Concomitant psychotropic therapy | “Requiring ongoing concomitant therapy with a psychotropic drug (other than as needed, anxiety medications, and pain control medications) and unable or unwilling to comply with the washout period.” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.4-3"></a>

###### Anxiety disorder diagnoses eligible, including generalized anxiety disorder

> “The goal was to include people with anxiety disorders or significant anxiety that was associated with LTI. LTI was defined as any severe somatic disease, such as a diagnosis of cancer or another advanced-stage potentially fatal illness.”
> “criteria for an anxiety disorder, including generalised anxiety disorder, social phobia and panic disorder, as indicated by the Structured Clinical Interview for the DSM-IV (SCID-IV), or have a score ≥40 on the state or trait STAI at study inclusion. Participants without LTI had to meet DSM-IV criteria for at least one anxiety disorder. Thus, in people without LTI, elevated STAI scores were not sufficient for inclusion.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.4-4"></a>

###### Recruitment

> “Participants were recruited through an advertisement that was placed on website homepages of the University Hospital Basel and Swiss Medical Society for Psycholytic Therapy (SAePT) trial registries, or by word of mouth.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Registered interventions

| Intervention | Quoted registry text |
| --- | --- |
| LSD | “Lysergic Acid Diethylamide 200ug per os, single dose” |
| Placebo | “Capsules containing mannitol looking identical to LSD” |
| Arm sequence | “Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.5-2"></a>

###### Study drug and placebo as described in the follow-up publication

> “LSD free base (>99% purity; Lipomed AG, Arlesheim, Switzerland) was administered as an oral solution in units that contained 100 μg LSD in 1 mL of 96% ethanol. Inactive placebo consisted of identical units that were filled with ethanol only.”
> “Randomisation and production were performed according to good manufacturing practice (GMP) by a licensed GMP facility (Apotheke Dr Hysek, Biel, Switzerland).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.5-3"></a>

###### Session setting, duration, and therapist

> “After successful screening, each person was assigned for the entire duration of the study to one investigator/therapist who conducted all treatment sessions and study visits. Treatment sessions lasted approximately 12 h, and study visits lasted approximately 1 h. Study visits consisted of talk therapy, followed by an assessment of adverse events, changes in general medication and administration of the questionnaires.”
> “Treatment sessions were conducted in a calm hospital room (University Hospital Basel) or calm practice room (Clinic Dr Peter Gasser). Only one participant and one investigator/therapist were present during the treatment sessions (exceptions of more than one therapist being present were made upon request by the therapist or participant).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.5-4"></a>

###### Background treatment: LSD given as an add-on

> “However, most people had already received some therapy (e.g. anxiolytics, antidepressants or talking psychotherapy) when they entered the trial, and antidepressant treatment was only tapered off for LSD/placebo sessions.”
> “LSD therapy therefore served as an add-on for those who had already received treatment at trial inclusion.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.5-5"></a>

###### Additional psychedelic sessions after the trial

> “Six individuals from the original study continued psychedelic therapy (LSD, 3,4-methylenedioxymethamphetamine (MDMA) or psilocybin) within the Swiss limited-use programme and underwent one to four additional psychedelic sessions (all LSD).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using State-Trait Anxiety Inventory Global Score as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Quoted registry text |
| --- | --- |
| Primary | “Reduction in anxiety assessed by questionnaires (STAI) 16 weeks after LSD compared with placebo” |
| Primary time frame | “16 weeks post-intervention” |
| Secondary: depression | “Reduction in depression will be assessed by questionnaires (HDRS, BDI) 2, 8 and 16 weeks after LSD compared with placebo” |
| Secondary: anxiety at earlier visits | “Reduction in anxiety will be assessed by questionnaire (STAI) 2 and 8 weeks after LSD compared with placebo” |
| Secondary: psychopathology | “Reduction of psychopathological symptoms will be assessed by questionnaire (SCL-90) 2, 8, and 16 weeks after LSD compared with placebo” |
| Secondary: sustained response | “Follow-up using different questionnaires to compare (within-subject) the 52-week response with Responses from baseline and 16-weeks.” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.6.1-2"></a>

###### Primary endpoint as published: STAI-Global score at 16 weeks

> “The primary end point was anxiety symptoms 16 weeks after the last treatment session, assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients. Further outcome measures included ratings for depression symptoms (Beck Depression Inventory and Hamilton Depression Rating Scale, 21-item version) and ratings for acute subjective drug effects.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.6.1-3"></a>

###### Purpose of the STAI global score as stated by the sponsor

> “The primary efficacy endpoint was reduction in anxiety symptoms 16 weeks after the last LSD or placebo administration. The primary outcome measure was the State Trait Anxiety Inventory (STAI) global score, which is used to assess the severity of anxiety symptoms.”
> “Secondary outcome measures included improvements in Hamilton Depression Scale (HAM-D), Beck Depression Index (BDI), and several other major psychiatric symptoms (Symptom-Check-List-90-R) scores.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.6.1-4"></a>

###### Response and remission definitions

> “The clinical response was defined as a STAI-G reduction ≥ 30%.”
> “Remission was defined as score <80 for the STAI-G.”
> “Remission was defined as score <10 for the BDI; only patients with a score of ≥10 at screening were included.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.6.1-5"></a>

###### Outcome measures of the long-term follow-up

> “The primary outcome measure in the present study was defined the STAI-G (with the primary end-point 16 weeks after the last treatment session, as reported previously).”
> “Secondary outcomes that were assessed during the study and at the follow-up were scores on the STAI-State (STAI-S), STAI-Trait (STAI-T), BDI and SCL-90-R.”
> “At follow-up, in addition to the therapeutic outcome questionnaires, a questionnaire about persisting effects of psychedelics was administered.”
> “Personality traits at screening and the 1-year follow-up were assessed using the 60-item NEO - Five-Factor Inventory (NEO-FFI)”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned sample in the registered summary

> “Participants: 40 patients aged > 25 years with anxiety disorder (according to DSM-IV or a state-trait anxiety inventory score >40 in the STAI trait or state scale) with or without life-threatening illness.”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.7.1-2"></a>

###### Enrolled: 46 participants

> “Enrollment (Actual) 46”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

> “The trial enrolled 46 patients either suffering from anxiety symptoms in life-threatening illnesses or with an anxiety disorder without severe somatic illness.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.7.1-3"></a>

###### Analyzed in the primary analysis: 42 participants

> “assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.7.1-4"></a>

###### Analyzed at long-term follow-up

> “Follow-up questionnaires were returned by 35 individuals (15 in the group with LTI and 20 without LTI). People who had at least two LSD sessions and one outcome measure were included in the analysis. One person did not complete the STAI questionnaires, resulting in a total of 33 people for all STAI measures and 34 people for all other measures. A total of 39 participants (20 in the LSD-first group and 19 in the placebo-first group) were eligible for the change-from-baseline analysis per treatment group.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Primary analysis restricted to the first period because of carryover

> “The outcomes for the first period (between-subjects analysis) are primarily shown due to carryover effects.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.7.2-2"></a>

###### Follow-up analysis set and statistical model

> “People who had at least two LSD sessions and one outcome measure were included in the analysis.”
> “Outcomes were analysed using Linear Mixed Effects models, employing the lme4 and lmer test packages in R. Time points were used as the fixed factor, and participants were used as the random factor. For therapeutic outcomes but not personality traits, baseline values of the periods were considered covariates (change from baseline values for the respective period).”
> “Tukey's post hoc pairwise comparisons of least square means across time points were performed to elucidate significant differences between baseline and follow-up. These analyses were planned and hypothesised a priori in the protocol.”
> “Exploratory associations between the acute response to LSD and main follow-up outcome measures were assessed using Pearson's correlations.”
> “The criterion for significance was P < 0.05.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Enrolled and analyzed in the primary analysis

> “The trial enrolled 46 patients”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

> “assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.8.1-2"></a>

###### Participants contributing data at long-term follow-up

> “Detailed data on dropouts during the study were previously reported.”
> “Follow-up questionnaires were returned by 35 individuals (15 in the group with LTI and 20 without LTI).”
> “We received written feedback from 18 participants”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Duration of anxiety and prior treatment

> “On average, people were diagnosed with anxiety 10 ± 9 years (mean ± s.d.) prior to study inclusion (range: 0–39 years).”
> “Many of the participants in the present trial had a long history of treatment attempts/failures and were to some degree non-responsive chronic cases.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.2-2"></a>

###### Imbalance in symptom ratings between sequence groups

> “The most obvious difference between the two groups was that the placebo-first group had higher ratings in symptoms at inclusion, and this coincidental difference remained throughout the entire trial.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.2-3"></a>

###### Personality trait openness at study inclusion

> “Interestingly, the individuals in the present study had very high values in the trait openness at study inclusion compared with reference values from the general population”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Primary endpoint: STAI-Global change at 16 weeks (between-subjects analysis)

> “LSD treatment resulted in significant reductions of State-Trait Anxiety Inventory-Global scores up to 16 weeks after treatment (least-square mean [standard error] change from baseline difference = -16.2 [5.8], 95% CI, -27.8 to -4.5, d = -1.18, p = .007).”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.8.3-2"></a>

###### Depression: HAM-D-21 and BDI

> “Similar effects were observed for ratings of comorbid depression on the Hamilton Depression Rating Scale, 21-item version (-7.0 [1.9], 95% CI, -10.8 to -3.2, d = -1.1, p = .0004) and the Beck Depression Inventory (-6.1 [2.6], 95% CI, -11.4 to -0.9, d = -0.72, p = .02).”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.8.3-3"></a>

###### STAI-G response and time course reported at the oral presentation

> “A clinical response (reduction in STAI-G scores ≥30%) was observed in 65% (13/20) patients in the LSD arm and in 9% (2/22) patients in the placebo arm (p=0.003). Effects were maximal 2 weeks after the second LSD session and sustained up to 16 weeks.”
> “All secondary endpoint measurements, including the HAM-D-21, BDI, and SCL-90-R, showed similarly rapid and sustained responses consistent with a lasting treatment effect on anxiety, depression, and general psychiatric symptomatology.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.8.3-4"></a>

###### Acute subjective effects and long-term anxiety reduction

> “Positive acute subjective drug effects and mystical-type experiences correlated with the long-term reductions in anxiety symptoms.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

> “Correlations between acute LSD effects and long-term outcomes showed a significant correlation between ΔSTAI-G measures and mystical-type experiences (total MEQ30 score; r p = −0.342, P = 0.048)”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.3-5"></a>

###### Follow-up at 12 months after the end-of-study visit: STAI-G change from baseline

> “Participants reported a sustained reduction of STAI-G scores compared with baseline (least square means (95% CI) = −21.6 (−32.7, −10.4), d = 1.04, P < 0.001, for those who received LSD in the first period (94 weeks after the last LSD treatment) and −16.5 (−26.2, −6.8), d = 1.02, P < 0.05, for those who received LSD in the second period (68 weeks after the last LSD treatment)).”
> “The LSD-first group improved significantly on the STAI-G compared with the primary end-point (16 weeks after last drug administration) at follow-up. The least square mean (95% CI) change was −9.7 (−15.5, −4.0), while the placebo-first group showed no further improvement: 1.2 (−4.2, 6.6).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.3-6"></a>

###### Follow-up at 12 months: depression

> “Similar effects were observed for comorbid depression with change from baseline BDI scores of −8.1 (−13.2, −3.1), d = 0.71, P < 0.01, and −8.9 (−12.9, −4.9), d = 1.21, P < 0.01, for the LSD-first and placebo-first groups, respectively.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.3-7"></a>

###### Follow-up at 12 months: remission and response

> “At follow-up, a total of 11 participants (33%) were in remission with regard to anxiety symptoms, and a total of 17 participants (49%) were in remission with regard to depression symptoms”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

| Follow-up row (Table 2, week 102) | LSD first, % | LSD first, n | Placebo first, % | Placebo first, n | All, % | All, n |
| --- | --- | --- | --- | --- | --- | --- |
| STAI-G remission (score <80) | “56” | “9” | “12” | “2” | “33” | “11” |
| STAI-G response (reduction of ≥30%) | “56” | “9” | “35” | “6” | “45” | “15” |
| BDI remission (score <10) | “56” | “9” | “42” | “8” | “49” | “17” |

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.3-8"></a>

###### Subgroups: life-threatening illness, further psychedelic therapy, and generalized anxiety disorder

> “Post hoc tests revealed no significant differences between people with and without LTI (P = 0.45 for the LSD-first group and P = 0.41 for the placebo-first group), people whose therapy was continued within the Swiss limited-use programme (P = 0.89 for the LSD-first group and P = 0.66 for the placebo-first group) and people with a formal diagnosis of generalised anxiety disorder (GAD; P = 0.35 for the LSD-first group and P = 0.65 for the placebo-first group).”
> “The present study included participants with a range of anxiety diagnoses that were included based on their symptom severity; this approach is supported by the findings that we found no difference in response between the groups (LTI versus non-LTI) and diagnosis (GAD versus non-GAD).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### Persisting Effects Questionnaire at follow-up

> “On the PEQ, high ratings of positive attitudes about life and/or self, positive mood changes, altruistic/positive social effects and positive behavioural changes were reported (all >47% of the total maximum score), whereas ratings of the negative counterparts remained low (all <10% of the total maximum score).”
> “On average, people rated the experience as ‘among the ten most personally meaningful experiences in life’, as ‘very much’ spiritually meaningful and as having positively influenced their sense of well-being or life satisfaction”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.4-2"></a>

###### Personality traits (NEO Five-Factor Inventory)

> “Personality trait neuroticism decreased (P < 0.0001) and trait extraversion increased (P < 0.01) compared with study inclusion.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.4-3"></a>

###### General psychiatric symptoms (SCL-90-R)

> “Participants reported sustained reductions of anxiety, depression and general psychiatric symptomatology up to 12 months after the end-of-study visit compared with baseline measures”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.4-4"></a>

###### Written participant feedback at follow-up

> “We received written feedback from 18 participants, which included the following topics: therapeutic potential of LSD (14 participants; 13 positive, one negative), setting and atmosphere (five participants; three positive, two negative), guide/therapist interaction (two participants; one positive, one negative), dose-related feedback (two participants; both negative (one participant reported the dose was too high, and one participant reported the dose was too low)), post-session effects (two participants; one positive, one negative) and comparison between dosing days (one participant; negative).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Acute untoward effects and treatment-related serious adverse event

> “Transient, mild, acute untoward effects of LSD treatment were reported by 8 patients (19%). One treatment-related serious adverse event (acute transient anxiety) occurred (2%).”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.8.5-2"></a>

###### Serious adverse event description and suicidality

> “LSD was well-tolerated: only one SAE was considered related to treatment and consisted of acute transient anxiety and delusions during an LSD session. There were no recorded instances of treatment-emergent suicidal ideation with intent, suicidal behavior or intentional self-injury.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.8.5-3"></a>

###### Long-term safety: flashbacks and hallucinogen persisting perception disorder

> “Additionally, the follow-up questionnaire included questions about adverse effects, including flashbacks and hallucinogen persisting perception disorder (HPPD; see Supplemental Information for detailed questions)”
> “No additional adverse events were reported in the follow-up period, and no additional clinically relevant flashback phenomena or HPPD occurred.”
> “LSD did not induce any long-term adverse events, such as flashbacks or HPPD.”
> “Lasting negative effects were minimal.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

NCT03153579 was an investigator-initiated phase 2 crossover trial at two centers in Switzerland (University Hospital Basel and a private practice in Solothurn), funded by University Hospital Basel and the Swiss Medical Society for Psycholytic Therapy. The registered summary planned 40 participants; 46 were enrolled, and 42 were included in the primary analysis. Because of carryover effects, the primary results are a between-subjects comparison of the first period, in which a STAI-G response (reduction of 30% or more) was reported for 13 of 20 participants (65%) receiving LSD and 2 of 22 (9%) receiving placebo. The response figures come from the May 2022 company announcement of an oral presentation; the primary publication reports the least-squares mean difference of -16.2 points (95% CI, -27.8 to -4.5) at 16 weeks.

The population combined participants with an anxiety disorder and participants with anxiety associated with a life-threatening illness, for whom a STAI score of 40 or more could substitute for a DSM-IV diagnosis; eligible diagnoses included generalized anxiety disorder, social phobia, and panic disorder, and the follow-up post hoc tests found no difference in STAI-G change between participants with and without a formal GAD diagnosis (P = 0.35 and P = 0.65). The primary endpoint was a self-reported questionnaire, and the follow-up authors state that no objective, interview-based data and no measure of expectancy were collected. The placebo-first group had higher symptom ratings at inclusion, a difference that remained throughout the trial.

Each participant received LSD 200 μg in two sessions of approximately 12 hours with one investigator or therapist, and study visits included talk therapy. The follow-up publication describes the study drug as LSD free base in an oral solution of 96% ethanol (100 μg per mL) with an ethanol-only placebo, while the registry describes placebo capsules containing mannitol. Most participants had received anxiolytics, antidepressants, or psychotherapy before entry, antidepressants were tapered only for the sessions, and the authors state that LSD served as an add-on treatment; the participants were described as having a long history of treatment attempts and failures, with anxiety diagnosed a mean of 10 years before inclusion.

The 12-month follow-up had no control group, since all participants had received LSD by then. Questionnaires were returned by mail by 35 participants, with 33 contributing STAI measures, and 6 participants continued psychedelic therapy in the Swiss limited-use programme with one to four additional LSD sessions. The authors state that it is largely unclear what therapy participants received between the end-of-study visit and follow-up. The primary publication reports transient, mild acute untoward effects in 8 participants (19%) and one treatment-related serious adverse event of acute transient anxiety (2%), which the company announcement describes as acute transient anxiety and delusions. The registry has no posted results.

Two authors are consultants for Mind Medicine, Inc., which licensed the knowhow and data owned by University Hospital Basel; the authors state that the company had no role in financing, planning, or conducting the follow-up study, and the company states that it has exclusive access and rights to the data.

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/); [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/); [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579); [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.9-2"></a>

###### Limitations stated by the authors of the follow-up

> “The present study also has limitations. The present analysis included no control group for long-term effects of LSD. Additionally, no objective, interview-based data were collected, the herein-reported data are based on self-report questionnaires and no measure of expectancy was collected. All participants received LSD within this crossover study. Lasting effects were compared with measures before LSD-assisted therapy over time and within subjects. Therefore, we cannot exclude the possibility that other factors contributed to the long-term effects. Furthermore, it is largely unclear what therapy people received between the end-of-study visit and the follow-up.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.9-3"></a>

###### Treatment expectancy and differences between sequence groups

> “However, it remains unclear why individuals in the LSD-first group appeared to benefit more from LSD-assisted therapy compared with those who received placebo first.”
> “This also raises a question about treatment expectancy and whether people in the placebo-first group felt disadvantaged by not receiving LSD in the first period and whether this motive remained intact and influenced the subsequent therapeutic response.”
> “Also, the two placebo sessions in the second period could have served as additional integration sessions in those who received LSD in the first period.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.9-4"></a>

###### Additional sessions outside the trial

> “There was no significant difference in the primary treatment outcome (STAI-G) at follow-up compared with those who had no further psychedelic-assisted therapy, although an important consideration is the small sample size (n = 6).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.5"></a>

#### 3.1.5 LDA1

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Registered purpose

> “This study will find out whether psychotherapy combined with lysergic acid diethylamide (LSD) is safe and is helpful in people who are anxious because they have a potentially fatal disease.”
> “This study will examine whether two sessions of LSD-assisted psychotherapy scheduled two to four weeks apart will reduce anxiety and improve quality of life for people experiencing anxiety as a result of a potentially fatal illness.”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.1-2"></a>

###### Published objective

> “A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases.”
> “The present LSD study was designed to evaluate previous findings applying current research methodology.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.1-3"></a>

###### Objective of the qualitative follow-up

> “Participants of this study were included in a prospective follow-up.”
> “A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study identifiers, dates, and status

| Item | Registry record |
| --- | --- |
| Other study ID | “LDA1” |
| Phase | “Phase 2” |
| Study start | “2008-02” |
| Primary completion (actual) | “2011-04-14” |
| Study completion (actual) | “2012-09” |
| First posted (estimated) | “2009-06-15” |
| Results first posted | “2021-12-08” |
| Last update posted | “2023-07-12” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.2-2"></a>

###### Site: one private practice in Switzerland

> “This study has 1 location”
> “Solothurn, Switzerland Private Practices of Peter Gasser MD”
> “Sponsor Multidisciplinary Association for Psychedelic Studies”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.2-3"></a>

###### Recruitment and visit period as published

> “Recruitment took place from 2007 to 2011 until all planned participants were enrolled, and study visits were completed from 2008 to 2012.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Official title and registered design

> “LSD-assisted Psychotherapy in Persons Suffering From Anxiety Associated With Advanced-stage Life Threatening Diseases. A Phase-II, Double-blind, Placebo-controlled Dose-response Pilot Study”
> “This study will be a randomized, active placebo controlled,double-blind pilot study of the safety and efficacy of LSD-assisted psychotherapy as a way of reducing anxiety in people with potentially fatal illnesses.”
> “The randomized part of the study will last three and a half months (14 weeks).”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

| Design element | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.3-2"></a>

###### Active placebo control and open-label crossover

> “This phase 2 double-blind, active placebo-controlled, randomized clinical trial”
> “Two months after the second experimental session, a follow-up evaluation was completed, and the treatment period was finished by breaking the blind for each individual. The participants who received the active placebo could cross over to an identical but open-label treatment with 200 μg of LSD. A long-term follow-up evaluation was conducted 12 months after the last experimental session with LSD in either the blinded portion of the study or the open-label crossover.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.3-3"></a>

###### Ethics and regulatory approvals

> “was approved by the Ethics Committee of the Canton of Aargau, Swissmedic, the Swiss Federal Office for Public Health (Bundesamt fuer Gesundheit [Swiss Ministry of Health]), and the US Food and Drug Administration (Investigational New Drug no. 101,825) and was conducted in accordance with Good Clinical Practices.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.3-4"></a>

###### Funding and sponsor

> “This study was funded in part by Schweizerische Aerztegesellschaft für Psycholytische Therapie (Swiss Medical Society for Psycholytic Therapy) and Multidisciplinary Association for Psychedelic Studies. Rick Doblin (president) and Berra Yazar-Klosinski are employees of the main sponsor MAPS. Peter Gasser is president of SAEPT.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.3-5"></a>

###### Qualitative follow-up design

> “12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Life-threatening illness | “Have a diagnosis of advanced-stage potentially fatal illness.” |
| Illness types | “As well as metastatic cancer this may include autoimmune, neurological, infectious or rheumatoid diseases as well.” |
| Survival | “The participant must have a probability of survival of more than six months.” |
| Anxiety diagnosis or severity | “Meet DSM-IV criteria for Anxiety Disorder as indicated by the SCID or have a score of at least 40 on each part of the STAI.” |
| Prior treatment | “Have failed to respond adequately or at all to medication or psychotherapy intended to reduce anxiety, or have refused to take anxiolytic medication.” |
| Other affective disorders | “May be diagnosed with another affective disorder other than anxiety disorder, except bipolar-I disorder.” |
| Age | “Are at least 18 years of age.” |
| Psychiatric medication | “Are willing to withdraw from taking any psychiatric medications during the experimental session period.” |
| Washout | “Drugs must be discontinued long enough before the first LSD treatment session to avoid the possibility of a drug-drug interaction (the interval will be at least 5 times the particular drug's half-life).” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.4-2"></a>

###### Exclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Pregnancy and contraception | “Women who are pregnant or nursing, or of child bearing potential and are not practicing an effective means of birth control.” |
| Psychotic disorder | “Anyone with past or present diagnosis with a primary psychotic disorder.” |
| Dissociative or bipolar disorder | “Meeting DSM-IV criteria for Dissociative Disorder or Bipolar-I Affective Disorder.” |
| Substance use | “Meeting DSM-IV criteria for abuse of or dependence on any substance (other than caffeine or nicotine) in the past 60 days.” |
| Liver function | “No sufficient liver function at the baseline examination or the day before the experimental sessions.” |
| Central nervous system involvement | “Having evidence of CNS affection from the primary disease (e.g. brain metastasis), shown by neurocognitive impairment.” |
| Body weight | “Weighing less than 45 kg.” |
| Suicide risk | “Reasonably judged to present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study.” |
| Concomitant psychotropic therapy | “Requiring ongoing concomitant therapy with a psychotropic drug (other than as needed, anxiety medications, and pain control medications) and are unable or unwilling to comply with the washout period.” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.4-3"></a>

###### Eligibility as published: STAI threshold and exclusions

> “Individuals with current alcohol or drug dependence (except caffeine or nicotine); primary psychotic, bipolar I affective, or dissociative disorders; and neurocognitive impairment and women who were pregnant or nursing were excluded from this study. All participants reported a score of greater than 40 on either the state or the trait scale of the Spielberger State-Trait Anxiety Inventory”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.4-4"></a>

###### Recruitment

> “The participants were recruited through general information about the study reported in media, by flyers, presentations in hospitals or cancer support groups, or referral from other physicians.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Registered treatment arms

| Arm | Quoted registry text |
| --- | --- |
| Full dose LSD | “200 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.” |
| Active placebo LSD | “20 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.” |
| Therapy | “Therapy provided by male and female co-therapists” |
| Randomization ratio | “Subjects in this study will have a 66% of receiving the full dose of 200 mcg LSD, and they have a 33% chance of getting the active placebo dose of 20 mcg LSD.” |

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.5-2"></a>

###### Study drug: LSD free base capsules

> “LSD was supplied as free base by Lipomed (Arlesheim, Switzerland). Capsules consisting of 200 μg (experimental dose) and 20 μg of LSD (active placebo) were prepared by Bichsel Laboratories (Interlaken, Switzerland).”
> “Capsules were of identical size, color, and shape and were bottled in sequentially numbered containers.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.5-3"></a>

###### Experimental sessions and dose selection

> “The primary intervention consisted of two full-day experimental sessions scheduled 2 to 3 weeks apart with a male/female co-therapist team, embedded within an ongoing process of drug-free psychotherapy sessions for preparatory and integrative purposes. The participants were randomly assigned to the experimental dose groups, receiving either an oral dose of 200 μg of LSD (n = 8) or an active placebo of 20 μg of LSD (n = 4). The experimental dose was a moderate amount expected to produce the full spectrum of a typical LSD experience, without fully dissolving normal ego structures. The 20-μg dose of LSD was chosen as an active placebo to produce short-lived, mild, and detectable LSD effects that would not substantially facilitate a therapeutic process.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.5-4"></a>

###### Session setting, duration, and psychotherapy

> “Two preparatory psychotherapy sessions served to discuss the participant’s history, social situation, personality, health, mind-set, and emotional situation”
> “Other than going to the bathroom, the participants remained in the treatment room for the entire 8-hour experimental session and overnight with an attendant nearby.”
> “The therapeutic session ended after 8 hours, when the acute effects had subsided, followed by a brief review of the day’s experiences. After each experimental session, three drug-free psychotherapy sessions lasting 60 to 90 minutes took place, during which the participant’s experiences were reviewed for integration and deepening the therapeutic process.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.5-5"></a>

###### Concomitant medications and restrictions

> “The participants were required to taper off of antidepressants and antianxiety medications, to avoid alcohol and recreational drugs for 24 hours before, and to abstain from driving for 24 hours after the experimental sessions.”
> “During the study, two participants (both experimental dose) received concomitant selective serotonin reuptake inhibitor (SSRI) treatment for depression and tapered off of these medications five half-lives before each experimental session because SSRIs may attenuate the effects of the serotonergically active experimental drug”
> “Three participants received benzodiazepines (two experimental dose and one active placebo) as needed.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using State-Trait Anxiety Inventory Score as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### STAI as the primary outcome measure

> “The STAI Form X, a widely used self-report instrument for assessing state and trait anxiety in adults, served as the primary outcome measure of anxiety symptoms.”
> “Outcome measures were completed at baseline, 1 week after experimental sessions, 2-month follow-up, and 12-month follow-up.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.6.1-2"></a>

###### Registered primary outcome and scale description

> “Primary Endpoint State-Trait Anxiety Inventory (STAI)”
> “The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety.”
> “STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety.”
> “2 months after second experimental session”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.6.1-3"></a>

###### Trait anxiety as an outcome

> “Trait anxiety is not expected to be altered by short-term psychotherapy”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.6.1-4"></a>

###### Secondary outcome measures

> “Secondary outcome measures included the European Cancer Quality of Life Questionnaire 30-item version 1.0”
> “the SCL-90-R”
> “and the Hospital Anxiety and Depression Scale”
> “After each experimental session, the State of Consciousness Questionnaire was completed”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Screened, enrolled, and randomized

> “Of 70 participants who were evaluated for eligibility by telephone or e-mail, 20 were further screened in person, and 12 were enrolled in this study”
> “The participants received either 200 μg of LSD (n = 8) or 20 μg of LSD with an open-label crossover to 200 μg of LSD after the initial blinded treatment was unmasked (n = 4).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

> “Enrollment (Actual) 12”

Source: [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-3.1.5.7.1-2"></a>

###### Analyzed: 8 and 3 participants

> “One active placebo participant was excluded from analysis after completing all study procedures because of a correction in the diagnosis of the qualifying disease state, which no longer satisfied the inclusion criteria.”
> “Values are mean ± SEM of changes from baseline in eight subjects in the LSD group and three subjects in the placebo group.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.7.1-3"></a>

###### Sample size basis

> “As a pilot study, this study had limited sample size, which reduced precision in effect size estimates and significance testing. The sample size selected was sufficient for a study primarily focused on safety and feasibility.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.7.1-4"></a>

###### Participants assessed at 12 months in the qualitative follow-up

> “12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Statistical methods and multiplicity

> “Repeated-measures analysis of variance (ANOVA) was used to test for significant changes in anxiety from baseline to subsequent posttreatment measurements. STAI trait and STAI state were analyzed in separate ANOVAs. To account for multiplicity, the alpha level indicating significance was adjusted to 0.025 (two tailed). Effect sizes were estimated using Cohen’s d techniques. Results of the 12-month follow-up were compared with those of the 2-month follow-up with paired t-tests. Secondary outcome measures conducted for exploratory purposes were not used for significance testing to reduce multiplicity.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.7.2-2"></a>

###### Handling of missing data and exclusion from analysis

> “We were unable to obtain results for two subjects (one experimental dose, one active placebo) from the assessment conducted 1 week after the second experimental session because of intervening cancer treatments. To avoid substantially reducing the sample size because of missing data, the assessment 1 week after the second experimental session was dropped for all subjects from analysis of outcomes. One active placebo participant was excluded from analysis after completing all study procedures because of a correction in the diagnosis of the qualifying disease state, which no longer satisfied the inclusion criteria.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Registry participant flow

| Period and status | Full dose LSD (200 mcg), blinded stage 1 | Active placebo LSD (20 mcg), stage 1 | Full dose LSD (200 mcg), open-label stage 2 |
| --- | --- | --- | --- |
| Stage 1 started | “8” | “4” | “0” |
| Stage 1 completed | “7” | “4” | “0” |
| Stage 1 not completed: adverse event | “1” | “0” | “0” |
| Stage 2 started | “0” | “0” | “3” |
| Stage 2 completed | “0” | “0” | “3” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.1-2"></a>

###### Crossover to open-label treatment

> “The crossover group (n = 3) shows a positive trend of STAI state and trait score reduction.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Registry baseline characteristics

| Characteristic | Full dose LSD (200 mcg) | Active placebo LSD (20 mcg) | Total |
| --- | --- | --- | --- |
| Participants | “8” | “3” | “11” |
| Age, years, mean (SD) | “49.6(8.4)” | “57.4(9.9)” | “51.7(9.1)” |
| Female | “3” | “1” | “4” |
| Male | “5” | “2” | “7” |
| History of suicidal tendencies: none | “8” | “1” | “9” |
| History of suicidal tendencies: mild | “0” | “2” | “2” |
| Metastatic breast carcinoma | “3” | “1” | “4” |
| Metastatic gastric carcinoma | “2” | “0” | “2” |
| Plasmocytoma | “1” | “0” | “1” |
| Non-Hodgkin's Lymphoma | “0” | “1” | “1” |
| Celiac Disease | “0” | “1” | “1” |
| Parkinson's Disease | “1” | “0” | “1” |
| Bechterew's Disease | “1” | “0” | “1” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.2-2"></a>

###### Baseline STAI scores (registry primary outcome at baseline, visit 4)

| STAI subscale, mean (SD) | Full dose LSD (200 mcg), n = 8 | Active placebo LSD (20 mcg), n = 3 |
| --- | --- | --- |
| STAI-state | “53.1(4.7)” | “47.7(7.7)” |
| STAI-trait | “53.2(4.3)” | “43.3(7.0)” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.2-3"></a>

###### Race and ethnicity not collected

> “Race and Ethnicity were not collected from any participant.”

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.2-4"></a>

###### Diagnoses and prior LSD experience

> “Eleven of the 12 subjects had no prior experience with LSD.”
> “half of the subjects were diagnosed with generalized anxiety disorder (GAD).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.2-5"></a>

###### Baseline comparability of STAI scores

> “No significant difference was found (p = 0.261) between group mean scores at baseline.”
> “No significant difference was found between the groups at baseline (p = 0.563).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Primary endpoint: STAI at 2 months after the second session (registry)

| STAI subscale, mean (SD) | Full dose LSD (200 mcg), n = 8 | Active placebo LSD (20 mcg), n = 3 |
| --- | --- | --- |
| STAI-state | “41.5(3.2)” | “51.7(5.3)” |
| STAI-trait | “45.2(3.7)” | “49.0(6.1)” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.3-2"></a>

###### Primary endpoint: published analysis

> “At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.3-3"></a>

###### Trait anxiety

> “The visit × group interaction testing for differences between the groups produced p = 0.033 (F = 4.151, df = 2,18), and observed statistical power was 65.6%, with results trending toward statistical significance. Comparing trait anxiety at baseline with 2-month follow-up yielded an effect size of 1.1. However, only three of eight experimental dose subjects dropped lower than the threshold value of 40 after the intervention. In contrast, all active placebo subjects experienced increases in trait anxiety.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.3-4"></a>

###### State anxiety

> “The visit × group interaction testing for differences between the groups produced p = 0.021 (F = 4.846, df = 2,18), and observed statistical power was 72.7%. Even controlling for multiplicity, the reductions in state anxiety were statistically significant 2 months after two experimental sessions of LSD-assisted psychotherapy. Comparing state anxiety at baseline with 2-month follow-up yielded an effect size of 1.2. However, only three of eight experimental dose subjects dropped lower than the diagnostic cutoff of 40 after the intervention. In contrast, two active placebo subjects experienced increases in state anxiety.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.3-5"></a>

###### Durability at 12 months

> “Comparison of 2-month and 12-month follow-up results in the subjects who received 200 μg of LSD in either the blinded sessions or the open-label crossover indicate that the benefits were sustained over time. The mean difference varied only by 0.667 between these assessments, and no significant difference was found with p = 0.825 (two tailed).”
> “Comparison of 2-month and 12-month follow-up results in the subjects who received 200 μg of LSD in either the blinded sessions or the open-label crossover indicates that the benefits were sustained over time. The mean difference varied only by 1.00 between these assessments, and no significant difference was found with p = 0.531 (two tailed).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

> “The significant benefits as measured with the STAI were sustained over a 12-month period.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="topic-3.1.5.8.3-6"></a>

###### Hospital Anxiety and Depression Scale

> “The experimental dose group mean (SD) anxiety scores decreased from 11.7 (3.4) to 8.1 (3.2) after two sessions, whereas the active placebo group anxiety scores decreased only from 11.3 (2.1) to 10.7 (3.0). The active placebo subjects who continued to the crossover experienced an even greater decline lower than the diagnostic cutoff for anxiety to 7.0 (2.6). All subjects who received the experimental dose were lower than the diagnostic cutoff at the 12-month follow-up, with a mean (SD) of 7.6 (4.5). The depression results also mirrored the anxiety results.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### Quality of life: EORTC-QLQ global health score

> “Global health scores from the EORTC-QLQ increased from a mean (SD) of 37.4 (10.0) at baseline to 50.0 (14.9) after treatment with two sessions of 200 μg of LSD, whereas mean scores decreased from 44.3 (12.7) to 36.0 (12.8) in the active placebo group.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.4-2"></a>

###### General psychopathology: SCL-90-R Global Severity Index

> “Global Severity Index (GSI) scores from the SCL-90-R decreased from a mean (SD) T-score of 69.6 (6.7) at baseline to 60.2 (7.2) in the experimental dose group whereas increasing from 66.0 (15.1) to 67.7 (10.2) in the active placebo group. The active placebo group experienced an improvement comparable with the full-dose group after receiving the experimental dose in the open-label crossover, with mean (SD) T-scores dropping to 57.3 (15.0).”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.4-3"></a>

###### Participant-reported changes at 12 months (qualitative content analysis)

> “In the QCA participants consistently reported insightful, cathartic and interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of life (66.7%).”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Severe and related adverse events as published

> “Neither the experimental dose (200 μg of LSD) nor the active placebo (20 μg of LSD) produced any drug-related severe adverse events, that is, no panic reaction, no suicidal crisis or psychotic state, and no medical or psychiatric emergencies requiring hospitalization.”
> “The experimental dose subjects experienced more types of AEs (n = 18) than the active placebo subjects (n = 8). In general, AEs were reported more frequently and with increased intensity in the experimental dose sessions. Interestingly, fewer reports of anxiety were received during experimental sessions with 200 μg (22.7%) than with active placebo (50%), and the mean intensity of anxiety was comparable between the groups. However, the subjects reported experiencing mild-to-moderate emotional distress similarly in experimental dose sessions (36.4%) and active placebo sessions (33.3%). Most AEs resolved when drug effects diminished. Only six reports of mild related AEs (illusions, feeling cold or abnormal, and some emotional distress) persisted until the next day. No flashback phenomena or other prolonged effects were observed.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.5-2"></a>

###### Vital signs and rescue medication

> “LSD did not significantly alter blood pressure or heart rate”
> “Three participants received pain medication during the study, only one of which was required as rescue medication for a treatment-emergent AE. Acetaminophen was required for this participant for a moderate headache the day after an experimental dose session.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.8.5-3"></a>

###### Registry adverse events: mortality, serious, and selected other adverse events

> “From enrollment to end of Stage 2 (approximately 11 months)”
> “Indicates events were collected by non-systematic assessment”

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

| Adverse event (affected / at risk) | Full dose LSD (200 mcg), stage 1 | Active placebo LSD (20 mcg), stage 1 | Full dose LSD (200 mcg), stage 2 |
| --- | --- | --- | --- |
| All-cause mortality | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Serious adverse events, total | “1/8 (12.50%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Serious: metastatic esophageal cancer | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Serious: pyelonephritis | “0/8 (0.00%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Other adverse events, total | “8/8 (100.00%)” | “4/4 (100.00%)” | “3/3 (100.00%)” |
| Feeling cold | “6/8 (75.00%)” | “0/4 (0.00%)” | “1/3 (33.33%)” |
| Illusions | “6/8 (75.00%)” | “1/4 (25.00%)” | “2/3 (66.67%)” |
| Emotional distress | “5/8 (62.50%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Feeling abnormal | “5/8 (62.50%)” | “2/4 (50.00%)” | “1/3 (33.33%)” |
| Time perception altered | “4/8 (50.00%)” | “0/4 (0.00%)” | “2/3 (66.67%)” |
| Mydriasis | “3/8 (37.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Anxiety | “2/8 (25.00%)” | “2/4 (50.00%)” | “1/3 (33.33%)” |
| Impaired gait | “2/8 (25.00%)” | “0/4 (0.00%)” | “2/3 (66.67%)” |
| Hallucination | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |

Source: [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.8.5-4"></a>

###### Long-term adverse reactions at 12 months

> “None of the participants reported lasting adverse reactions.”

Source: [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

LDA1 was a phase 2 pilot trial at one private practice in Solothurn, Switzerland, with the Multidisciplinary Association for Psychedelic Studies (MAPS) named as main sponsor; MAPS co-funded the trial, and the funding statement names two MAPS employees. Twelve participants with anxiety associated with life-threatening diseases were randomized to LSD 200 μg (8 participants) or an active placebo of LSD 20 μg (4 participants); one active placebo participant was excluded from analysis after a correction of the qualifying diagnosis, leaving 8 and 3 participants. The authors state that the sample size was sufficient for a study primarily focused on safety and feasibility and that the limited sample reduced precision in effect size estimates and significance testing.

With the alpha level adjusted to 0.025 for multiplicity, the reduction in state anxiety (p = 0.021) met the threshold and the reduction in trait anxiety (p = 0.033) did not. Only three of eight participants in the 200 μg group fell below the threshold of 40 on each subscale. The assessment 1 week after the second session was dropped for all participants because results were missing for two participants, and secondary outcomes were not tested for significance. The 12-month comparisons included participants who received 200 μg in the open-label crossover and had no concurrent control, and the qualitative follow-up tested 10 participants.

Blinding was not maintained: for all 24 blinded sessions, all participants correctly guessed the dose, and the authors state that the 20-μg dose was too low to achieve uncertainty about the dose. Half of the participants received a SCID diagnosis of generalized anxiety disorder, and the authors state that this does not mean the participants had the conventional pattern of psychopathology usually associated with GAD, because the SCID items do not differentiate GAD from a reaction to a life-threatening disease. The registry lists the illnesses as metastatic breast carcinoma (4 participants), metastatic gastric carcinoma (2), and plasmocytoma, non-Hodgkin's lymphoma, celiac disease, Parkinson's disease, and Bechterew's disease (1 each); mean age was 51.7 years, 7 of 11 participants were male, and race and ethnicity were not collected. The authors state that the course of the somatic illness may affect psychological parameters independent of the intervention, and that the EORTC-QLQ focused on physical aspects and was insufficient for evaluating long-term psychological changes.

The intervention combined LSD capsules with two preparatory psychotherapy sessions, three drug-free integrative psychotherapy sessions after each experimental session, and a male and female co-therapist team, with 8-hour experimental sessions and an overnight stay. The publication reports no drug-related severe adverse events; the registry reports serious adverse events of metastatic esophageal cancer (1 of 8) and pyelonephritis (1 of 4) and all-cause mortality of 1 of 8 in the 200 μg group. The registry and the publication differ on two details: the registry requires a score of at least 40 on each part of the STAI and spaces sessions two to four weeks apart, while the publication states that participants scored greater than 40 on either the state or the trait scale and that sessions were 2 to 3 weeks apart.

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/); [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/); [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387); [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)

<a id="topic-3.1.5.9-2"></a>

###### Limitations stated by the authors: sample size, blinding, and dose

> “As a pilot study, this study had limited sample size, which reduced precision in effect size estimates and significance testing.”
> “The imperfect blinding also limits the validity of the results.”
> “Although using a slightly higher LSD dose in the comparator group can increase blinding, it can also increase efficacy of the comparator, compromising the estimates of effect size. Given the safety of the moderate experimental dose, results might have been improved with a larger dose of 250 μg.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.9-3"></a>

###### Blinding assessment

> “For all 24 blinded sessions, all participants correctly guessed the dose of LSD that was administered, and both therapists guessed incorrectly in one active placebo session.”
> “This indicates that the 20-μg dose was too low to achieve successful uncertainty about the dose.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.9-4"></a>

###### Limitations stated by the authors: somatic illness and quality of life measure

> “Other limitations exist in treating participants with grave somatic diseases because the course of the somatic illness (e.g., worsening or improving) may substantially impact psychological parameters independent of the therapeutic intervention and contribute to missing data. The quality of life questionnaire (EORTC-QLQ), which was chosen as a secondary outcome measure, focuses extensively on physical aspects and was insufficient for evaluating long-term psychological changes.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.9-5"></a>

###### Applicability of the GAD diagnosis

> “Neither the SCID’s five items about GAD nor criterion E for GAD in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, differentiates between anxiety typically seen with GAD and a reaction to a life-threatening disease (and its consequences). Therefore, even though the SCID generates a diagnosis of GAD, this does not mean that the subjects had the conventional pattern of psychopathology usually associated with GAD.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="topic-3.1.5.9-6"></a>

###### Number of sessions

> “Most of the participants stated a preference for more than two LSD sessions and a longer treatment period. The results demonstrated a decrease in STAI scores most prominently after the second LSD session, suggesting that at least two LSD sessions are needed to demonstrate these effects.”

Source: [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

<a id="heading-3.1.6"></a>

#### 3.1.6 MM-120-101

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Comparison of the phase 2b capsule with the phase 3 orally disintegrating tablet

> “This phase 1 study compared the pharmacokinetic (PK), subjective effect, and safety profiles of the phase 2b capsule formulation at 100µg with a new 100µg orally disintegrating tablet (ODT) formulation that was subsequently included in the phase 3 program.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.1-2"></a>

###### Purpose of the bridging study stated in the annual report

> “In our Phase 2 clinical trials for DT120, we used a formulation of DT120 that did not include ODT technology.”
> “In 2024, we completed a pharmacokinetics”
> “bridging study to support the advancement of the DT120 ODT formulation into pivotal clinical trials, and we are using the DT120 ODT formulation in our Phase 3 clinical trials for GAD and MDD.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Registry record

| Item | Registry record |
| --- | --- |
| Scientific title | “Phase I trial: MM-120-101” |
| IRAS number | “1007602” |
| Sponsor | “Mind Medicine Inc” |
| Countries of recruitment | “United Kingdom” |
| Participating centre | “MAC Clinical Research Liverpool” |
| Participating centre | “MAC Clinical Research Manchester” |
| Date of first enrolment | “13/10/2023” |
| Date of final enrolment | “04/12/2023” |
| Completion date | “19/12/2023” |
| Overall study status | “Deferred” |

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="topic-3.1.6.2-2"></a>

###### Ethics approval

| Item | Research summary |
| --- | --- |
| REC name | “Wales REC 1” |
| REC reference | “23/WA/0112” |
| Date of REC opinion | “1 Sep 2023” |
| REC opinion | “Further Information Favourable Opinion” |

Source: [HRA Phase 1 PK study of MM-120 in healthy volunteers (2023)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-pk-study-of-mm-120-in-healthy-volunteers/)

<a id="topic-3.1.6.2-3"></a>

###### Number of sites

> “This was a phase 1, multicenter (two sites), open-label, randomized, 2-period, 2-sequence, cross-over, within-subject study”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.2-4"></a>

###### Deferred publication of registry details

> “The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.”
> “29/06/2026: The deferral expiry date was changed from 20/11/2026 to 19/12/2028.”

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Open-label, randomized, two-period crossover design

> “This was a phase 1, multicenter (two sites), open-label, randomized, 2-period, 2-sequence, cross-over, within-subject study designed to compare the plasma PK profile of 2 MM120 formulations in healthy adults aged 18 to 55 years.”
> “All participants received a single dose of each formulation (capsules or ODT) in separate evaluation periods, separated by a 2-week washout period between dosing.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.3-2"></a>

###### Full title of the study

> “A Phase 1, Open-label Study to Compare the Pharmacokinetics of Two Formulations of MM-120 in Healthy Volunteers”

Source: [HRA Phase 1 PK study of MM-120 in healthy volunteers (2023)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-pk-study-of-mm-120-in-healthy-volunteers/)

<a id="topic-3.1.6.3-3"></a>

###### Study schedule

| Period | Quoted study day |
| --- | --- |
| Screening | “-21 to -1” |
| Washout | “2-13” |
| Follow-up | “15-29” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

> “Study MM120-101 | ODT-PK Bridging”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.3-4"></a>

###### Registry design description

| Item | Registry record |
| --- | --- |
| Study design | “Phase 1 study in 30 healthy volunteers” |
| Primary study design | “Other” |
| Phase | “Phase I” |
| Intervention type | “Drug” |

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="topic-3.1.6.3-5"></a>

###### Assessments: plasma pharmacokinetics, subjective effects, and adverse events

> “Plasma concentrations of MM120 were determined by validated bioanalytical method.”
> “Subjective effects were assessed using the Visual Analogue Scales (VAS) and 5-Dimensional Altered States of Consciousness (5D-ASC) scale, and descriptive statistics were presented for each category.”
> “Adverse events (AEs) were summarized for each treatment group by system organ class and preferred term.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.3-6"></a>

###### Study design as described in the pooled safety analysis

> “Open-label, crossover in healthy volunteers”
> “Single 100-µg ODT or capsule”
> “2-week washout”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Entry criteria

| Criterion | Quoted entry criterion |
| --- | --- |
| Sex | “Men and Women” |
| Age | “Ages 18-55” |
| Health status | “Healthy volunteers” |
| Medications | “No prohibited medications” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.4-2"></a>

###### Registry eligibility fields

| Item | Registry record |
| --- | --- |
| Participant type | “Healthy volunteer” |
| Age group | “Adult” |
| Sex | “All” |
| Health condition studied | “Healthy volunteers” |

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Four 25 µg capsules and one 100 µg orally disintegrating tablet, in randomized sequence

> “Participants were randomized equally to receive either four 25-μg MM120 capsules followed by 100μg MM120 ODT or ODT followed by capsules.”
> “MM120 100μg (freebase-equivalent) is considered an acceptable therapeutic dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.5-2"></a>

###### Formulations named in the study schematic

> “MM120 Zydis ODT (100 µg)”
> “MM120 Capsule (100 µg)”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Plasma Pharmacokinetic Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Planned sample size

| Item | Registry record |
| --- | --- |
| Target sample size at registration | “30” |

Source: [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)

<a id="topic-3.1.6.7.1-2"></a>

###### Participants randomized and dosed with both formulations

> “A total of 29 participants were randomized, and 24 participants received each MM120 formulation as a single dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

> “29 participants total (actual)”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Pharmacokinetic analysis set

> “Company analysis of pharmacokinetic data from Study MM120-101. PK analysis based on n=24 subjects that completed both dosing sessions.”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.7.2-2"></a>

###### Analysis methods

> “The PK and analysis of relative bioavailability between the 2 formulations were performed using Phoenix WinNonlin.”
> “Terms used to identify AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA v26.0).”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.7.2-3"></a>

###### Safety analysis set in the pooled safety analysis

> “Phase 1 PK Bioavailability (n = 29)”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Randomized and completing both periods

> “A total of 29 participants were randomized, and 24 participants received each MM120 formulation as a single dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Pharmacokinetic comparison: abstract results

> “MM120 ODT showed a faster onset of plasma concentrations than MM120 capsules, retaining similar relative bioavailability for Cmax.”
> “For AUC, the GMR for MM120 ODT was 16% higher compared with MM120 capsules.”
> “The ODT formulation had bioavailability similar to that of the capsule. ODT absorption occurred faster compared with capsules and there was a more rapid onset of acute drug effects in the ODT formulation.”
> “This study demonstrated that 100µg MM120 ODT was an acceptable formulation to take forward in clinical development.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.8.3-2"></a>

###### Pharmacokinetic parameters by formulation

| PK parameter | MM120 capsule | MM120 ODT |
| --- | --- | --- |
| Tmax (hr) | “2.25” | “2.0” |
| Cmax (ng/mL) | “2.63” | “2.68” |
| AUC0-∞ (ng*hr/mL) | “15.7” | “18.7” |
| AUC>1ng/mL (ng*hr/mL) | “9.7” | “12.0” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.8.3-3"></a>

###### Geometric mean ratios relative to the capsule

| Parameter | Quoted geometric mean ratio |
| --- | --- |
| Cmax | “GMR: 1.02” |
| AUC0-∞ | “GMR: 1.17” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-3.1.6.8.3-4"></a>

###### Company-derived comparisons and their bases, March 2024

> “50% faster onset of action”
> “17% improved bioavailability”
> “23% increase in AUC at target conc.”
> “Reduced GI side effects”
> “Based on time to reach target concentration of >1 ng/mL.”
> “Based on comparison of geometric mean ratio of total area under the curve.”
> “Based on ratio of mean AUC>1ng/mL. Target concentrations defined as level above which perceptual effects are present.”
> “Based on a comparison between Phase 2b study of MM120 capsules in GAD versus PK bridging study of MM120 ODTs”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

###### Subjective drug effects on visual analogue scales

> “Similar to PK profiles, the VAS scores showed an earlier onset of effects for MM120 ODT compared with capsules.”
> “Maximum drug effect VAS scores were reported at 3 and 4 hours post-dose for participants receiving MM120 ODT or capsules, respectively.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Treatment-emergent adverse events by formulation: abstract

> “Twenty-three (79.3%) and 22 (75.9%) participants reported 69 and 65 TEAEs after receiving MM120 ODT and capsules, respectively.”
> “Of these, participants receiving MM120 ODT compared with capsules reported similar rates of visual hallucinations (58.6 vs 51.7%), euphoric mood (48.3 vs 41.4%), and illusion (20.7 vs 17.2%).”
> “Most TEAEs were mild to moderate after a single dose of both formulations and were consistent with the expected acute effects of MM120.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-3.1.6.8.5-2"></a>

###### Treatment-emergent adverse events in the pooled safety poster

| Measure | Phase 1 PK bioavailability study, DT120 ODT (n = 29) |
| --- | --- |
| Any TEAE | “25 (86.2)” |
| Mild | “15 (51.7)” |
| Moderate | “9 (31.0)” |
| Severe | “1 (3.4)” |

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-3.1.6.8.5-3"></a>

###### Serious adverse events, suicidality, and vital signs across the four pooled studies

> “Across all 4 studies, there were no treatment-related serious adverse events (AEs), hallucinogen persisting perception disorder, or deaths after treatment with DT120”
> “Similarly, there was no worsening of preexisting passive suicidal ideation, no active suicidal ideation or behaviors, and no evidence of session-induced suicidal ideation”
> “Changes in vital signs were not clinically significant”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

MM-120-101 was an open-label, randomized, two-period crossover study in healthy adults aged 18 to 55 years; it measured plasma pharmacokinetics, subjective effects, and adverse events, and enrolled no participants with GAD. Of 30 planned participants, 29 were randomized and 24 received both formulations; the pharmacokinetic analysis used those 24. Each formulation was given once at 100 µg, so the study does not inform repeated dosing or other dose levels.

Results come from an abstract, company presentations, and a safety analysis across four DT120 studies; publication of the registry record's full details is deferred to 19/12/2028. Sources differ on the pharmacokinetic summary: the abstract reports Cmax as similar, an AUC geometric mean ratio 16% higher with the ODT, and bioavailability similar to the capsule, while a company presentation describes 17% improved bioavailability (a geometric mean ratio of 1.17), a 23% increase in AUC at target concentration, and reduced gastrointestinal side effects based on a comparison between the phase 2b capsule study and this study. Sources also differ on adverse events with the ODT: the abstract reports 23 participants (79.3%) with TEAEs after the ODT, and the pooled safety poster reports 25 (86.2%) in a column labeled DT120 ODT (n = 29). The company's annual report states that the bridging study was completed in 2024, while the registry gives a completion date of 19/12/2023. The annual report states that the change in formulation could cause the product to perform differently, and one author names formulation bridging among the conditions on which adoption will depend.

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf); [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf); [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf); [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603); [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="topic-3.1.6.9-2"></a>

###### Risk stated by the company from the change in formulation

> “This change in formulation could cause DT120 to perform differently, cause unforeseen side effects or affect the results of our Phase 3 clinical trials.”
> “This could delay completion of our Phase 3 clinical trials, require us to conduct additional bridging clinical trials, repeat one or more clinical trials, increase clinical trial costs or delay or prevent the submission, or approval, of one or more NDAs for DT120.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-3.1.6.9-3"></a>

###### Formulation bridging named as a condition for adoption

> “Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.”

Source: [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
